CN114072413B - 一种c-Myc蛋白抑制剂及其制备方法和用途 - Google Patents
一种c-Myc蛋白抑制剂及其制备方法和用途 Download PDFInfo
- Publication number
- CN114072413B CN114072413B CN202080049295.5A CN202080049295A CN114072413B CN 114072413 B CN114072413 B CN 114072413B CN 202080049295 A CN202080049295 A CN 202080049295A CN 114072413 B CN114072413 B CN 114072413B
- Authority
- CN
- China
- Prior art keywords
- compound
- 400mhz
- nmr
- mmol
- myc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010087705 Proto-Oncogene Proteins c-myc Proteins 0.000 title claims abstract description 25
- 102000009092 Proto-Oncogene Proteins c-myc Human genes 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 229940121649 protein inhibitor Drugs 0.000 title claims abstract description 9
- 239000012268 protein inhibitor Substances 0.000 title claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims description 262
- 150000003839 salts Chemical class 0.000 claims description 9
- 208000032839 leukemia Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 208000025113 myeloid leukemia Diseases 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 20
- 230000009385 viral infection Effects 0.000 abstract description 4
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 3
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 3
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 157
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 114
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 69
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 58
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 58
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 57
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 56
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 48
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 47
- 239000007787 solid Substances 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 31
- 230000015572 biosynthetic process Effects 0.000 description 30
- 238000003786 synthesis reaction Methods 0.000 description 29
- 239000012074 organic phase Substances 0.000 description 26
- 238000001308 synthesis method Methods 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 25
- 238000000034 method Methods 0.000 description 24
- 238000001035 drying Methods 0.000 description 23
- 230000014509 gene expression Effects 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000011734 sodium Substances 0.000 description 19
- 239000002904 solvent Substances 0.000 description 18
- 235000019439 ethyl acetate Nutrition 0.000 description 16
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 16
- 239000002609 medium Substances 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 239000007821 HATU Substances 0.000 description 14
- 238000000605 extraction Methods 0.000 description 13
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 9
- 229940127007 Compound 39 Drugs 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- -1 hydroxy, amino Chemical group 0.000 description 7
- 201000007270 liver cancer Diseases 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 125000003545 alkoxy group Chemical class 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 208000014018 liver neoplasm Diseases 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108700020796 Oncogene Proteins 0.000 description 5
- 230000033115 angiogenesis Effects 0.000 description 5
- 229960001230 asparagine Drugs 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- QIGLJVBIRIXQRN-ZETCQYMHSA-N ethyl (2s)-2-amino-4-methylpentanoate Chemical compound CCOC(=O)[C@@H](N)CC(C)C QIGLJVBIRIXQRN-ZETCQYMHSA-N 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- 102000052575 Proto-Oncogene Human genes 0.000 description 4
- 108700020978 Proto-Oncogene Proteins 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 3
- WFSMJMTYIMFHPV-UHFFFAOYSA-N 2-(9h-fluoren-9-yl)acetic acid Chemical compound C1=CC=C2C(CC(=O)O)C3=CC=CC=C3C2=C1 WFSMJMTYIMFHPV-UHFFFAOYSA-N 0.000 description 3
- 208000003950 B-cell lymphoma Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 108091028690 C-myc mRNA Proteins 0.000 description 3
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 3
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 102000043276 Oncogene Human genes 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000008482 dysregulation Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- WMSUFWLPZLCIHP-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 9h-fluoren-9-ylmethyl carbonate Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)ON1C(=O)CCC1=O WMSUFWLPZLCIHP-UHFFFAOYSA-N 0.000 description 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000003998 progesterone receptors Human genes 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- KOFLVDBWRHFSAB-UHFFFAOYSA-N 1,2,4,5-tetrahydro-1-(phenylmethyl)-5,9b(1',2')-benzeno-9bh-benz(g)indol-3(3ah)-one Chemical compound C1C(C=2C3=CC=CC=2)C2=CC=CC=C2C23C1C(=O)CN2CC1=CC=CC=C1 KOFLVDBWRHFSAB-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- UOXJNGFFPMOZDM-UHFFFAOYSA-N 2-[di(propan-2-yl)amino]ethylsulfanyl-methylphosphinic acid Chemical compound CC(C)N(C(C)C)CCSP(C)(O)=O UOXJNGFFPMOZDM-UHFFFAOYSA-N 0.000 description 1
- VSMILISQVUOHED-UHFFFAOYSA-N 2-amino-1-(2,5-dimethoxyphenyl)propan-1-one Chemical compound COC1=CC=C(OC)C(C(=O)C(C)N)=C1 VSMILISQVUOHED-UHFFFAOYSA-N 0.000 description 1
- ZAZPDOYUCVFPOI-UHFFFAOYSA-N 2-methylpropylboronic acid Chemical compound CC(C)CB(O)O ZAZPDOYUCVFPOI-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 description 1
- SYKJOJSYQSVNOM-UHFFFAOYSA-N 9h-fluoren-9-ylazanium;chloride Chemical compound Cl.C1=CC=C2C(N)C3=CC=CC=C3C2=C1 SYKJOJSYQSVNOM-UHFFFAOYSA-N 0.000 description 1
- DNVJGJUGFFYUPT-UHFFFAOYSA-N 9h-fluorene-9-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)C3=CC=CC=C3C2=C1 DNVJGJUGFFYUPT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 206010003162 Arterial injury Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000212384 Bifora Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 101001082567 Caenorhabditis elegans Hypoxia-inducible factor 1 Proteins 0.000 description 1
- 102000007590 Calpain Human genes 0.000 description 1
- 108010032088 Calpain Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108091035710 E-box Proteins 0.000 description 1
- 206010052369 Encephalitis lethargica Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 206010023774 Large cell lung cancer Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000212322 Levisticum officinale Species 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091057508 Myc family Proteins 0.000 description 1
- 101710150912 Myc protein Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 102100032063 Neurogenic differentiation factor 1 Human genes 0.000 description 1
- 108050000588 Neurogenic differentiation factor 1 Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102100026558 Protein max Human genes 0.000 description 1
- 101710192572 Protein max Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 229910005965 SO 2 Inorganic materials 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- GTVXHTBGOYJORD-FVGYRXGTSA-N [(1s)-1-carboxy-2-(1h-indol-3-yl)ethyl]azanium;chloride Chemical compound Cl.C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 GTVXHTBGOYJORD-FVGYRXGTSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000009504 deubiquitination Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000007973 glycine-HCl buffer Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 102000053563 human MYC Human genes 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 239000001645 levisticum officinale Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- KCUNTYMNJVXYKZ-JTQLQIEISA-N methyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate Chemical compound C1=CC=C2C(C[C@H](N)C(=O)OC)=CNC2=C1 KCUNTYMNJVXYKZ-JTQLQIEISA-N 0.000 description 1
- LOTBYPQQWICYBB-UHFFFAOYSA-N methyl n-hexyl-n-[2-(hexylamino)ethyl]carbamate Chemical group CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000012301 transgenic model Methods 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
涉及一类c‑Myc蛋白抑制剂及其制备方法和用途，所述c‑Myc蛋白抑制剂可选择性的抑制c‑Myc蛋白，因此，可用于c‑Myc蛋白失调的相关疾病，如癌症、心脑血管疾病、病毒感染相关疾病等的预防和治疗。
Description
技术领域
本发明属于药物领域，具体涉及一种c-Myc蛋白抑制剂及其制备方法和用途。
背景技术
癌基因是指存在于细胞或病毒基因组内，其编码产物能转化正常细胞形成肿瘤的基因，当这类基因处于正常状态时即为原癌基因。经研究发现，原癌基因广泛存在于生物界，具有维持正常生理功能、调控细胞生长和分化等多种重要的功能，包括了ras家族、myc家族、myb家族、src家族、sis家族等。当受物理、化学、微生物等因素影响时，原癌基因可发生突变、扩增、激活，从而可以转化为癌基因，而癌基因编码产物可以在动物体内诱导肿瘤的发生。
人c-Myc原癌基因位于人染色体8q24，包含3个外显子和2个内含子，其中外显子1起调节作用，不参与编码蛋白，外显子2和外显子3共同编码的c-Myc蛋白。c-Myc蛋白由以下结构组，包含：N-端的转录激活结构域(transcriptional activation domain,TAD)，是激活靶基因表达所必需的，包含MBI和MBII这两个保守结构域；MBIII结构域，会影响c-Myc的转录和稳定性；PEST区域，参与调控c-Myc的水解作用；CAPN是钙蛋白酶裂解c-Myc的位点，截断的Myc-Nick会促进肿瘤的存活和转移；MBIV区域，参与细胞凋亡进程；NLS是核定位区域，调控Myc蛋白进入细胞核以及发挥其转录功能；C-端的螺旋-转角-螺旋亮氨酸拉链结构域(bHLH-LZ)可以与配体蛋白Max形成异二聚体，与特定的DNA序列结合并激活相关基因的转录(Herbst A et al.Oncogene 2004；23(21):3863-71)。c-Myc作为一种极不稳定的蛋白，在细胞中半衰期极短，主要通过泛素-蛋白酶体进行降解或通过去泛素化作用保持稳定，c-Myc能够调节细胞内的多种生物学功能，如细胞增殖、凋亡、细胞周期进展、细胞代谢和胚胎发育，在疾病的发生、发展及演进过程中起到非常重要的作用，尤其是在肿瘤的发生和进展过程中起到重要作用。
在正常细胞中，c-Myc的表达是被严格调控的。在静止期的细胞中，c-Myc的表达是很微量的，当有生长因子刺激时，c-Myc作为最初的应答基因快速积累，并在整个细胞周期中维持较高水平，影响下游靶基因的表达直到细胞进入静止期后又恢复到原有的水平(Magid R et al.J Biol Chem 2003；278(35):32994-9)。
大量的研究表明c-Myc与70％的肿瘤疾病密切相关，包括淋巴瘤、乳腺癌、前列腺癌、结肠癌、宫颈癌、多发性骨髓瘤、髓性白血病、黑色素瘤、骨肉瘤、恶性胶质瘤、小细胞肺癌以及成神经管细胞瘤。c-Myc能在多个方面促进肿瘤的发生和生长。c-Myc被激活后，其编码的蛋白过表达，引起细胞转化和肿瘤形成，Felsher等的研究发现，在小鼠造血细胞中构建c-Myc转基因模型，转基因的表达会导致恶性淋巴瘤和髓系肿瘤的发生。c-Myc调节细胞周期的作用在肿瘤细胞中更能发挥作用，加速细胞的增殖，而在体外敲除肿瘤细胞中的c-Myc后能够阻碍细胞增殖，使细胞周期停滞。在肿瘤的发生进程中，新生血管是其赖以生存的保障，在肿瘤内部低氧的环境下，低氧诱导因子-1α(HIF-1α)可以促进肿瘤血管生成，而c-Myc能够诱导HIF-1α的表达，促进血管生成，当下调c-Myc和HIF-1α最终会抑制血管内皮生长因子VEGF和血管形成。此外，多种肿瘤的预后不良与c-Myc的扩增相关，在c-Myc表达升高的子宫癌肉瘤中，即使是早期患者其复发率也达到30％～50％(Salvi S et al.Int JMol Sci,2014,15(7):12458-12468)。
c-Myc失调是多种类型B细胞淋巴瘤的特点，在这些淋巴瘤中，c-Myc过表达抑制正常B细胞的发育，导致细胞重编码。近70％的B细胞淋巴瘤还携带参与TCF3-ID3通路的上游调控因子突变，导致细胞存活率增加，其中c-Myc可以影响TCF3-ID3的调控，从而影响细胞周期蛋白3的表达，促进肿瘤细胞的增殖和生长(Petra Korac et al.Genes 2017,8,115)。
c-Myc在几乎各型白血病中都有表达，在1988年Wickstrom和Holt分别合成了c-Myc mRNA的反义寡聚脱氧核苷酸ASODN在体外与HL60细胞共培养，有效抑制了c-Myc的表达，细胞生长受到了抑制，并且抑制了白血病细胞集落的形成，表明了c-Myc基因在白血病发生中起重要作用。在其后的研究中发现急性淋巴细胞白血病和急性非淋巴细胞白血病c-Myc表达最强，慢粒(CML)、骨髓增殖异常综合征(MDS)和多发性骨髓瘤(MM)中c-Myc表达远低于急性白血病，但明显高于对照细胞。研究发现c-Myc mRNA高表达的患者很难再化疗药物的诱导下缓解，c-Myc表达越低，完全缓解率越高，无病生存期也越长(Evingerhodges MJ et al.Leukemia,1988,2(1):45.)。
在乳腺癌中，大约有30％的病人有c-Myc高表达的情况，而在一组临床数据中发现c-Myc高表达组的术后无病生存期相比正常表达组从大于6.4年下降为1.4年，并且在极端情况下，淋巴结阴性、雌激素和孕激素受体阳性、c-Myc低表达的术后复发率为0％，而有淋巴结转移，雌激素和孕激素受体阴性、高表达c-Myc的患者复发率为93％(Pertschuk etal.Cancer,1993,71(1):162)。
最近的研究发现在肝癌中c-Myc是最高表达的癌基因之一，并且发现在晚期肝纤维化患者和模型中经常检测到c-Myc的过表达，在小鼠模型慢性损伤发生后由于c-Myc的调节导致肝细胞凋亡，增殖增加，血小板来源的生长因子亚单位(PDGF-B)异常表达。肝硬化和慢性肝病常常导致肝癌，目前发现c-Myc基因的低甲基化和肝癌的发生发展有关，并且通过对小鼠实验模型研究发现在肝硬化和慢性肝病中可以作为新的标志物和治疗的新靶点(Kang Zheng et al.Genes 2017,8,123；doi:10.3390)。同时，c-Myc是肝癌预后不良的指标，而且c-Myc过表达患者生存期明显缩短，与原发性肝癌相比，转移性和复发性肝癌中检测到较高的c-Myc表达(Wang,Y.et al.Cancer 2002,95,2346–2352)。此外，肝癌细胞的转移是通过c-Myc的多种信号通路介导的(Pedica F et al.PLoS One,2013,8(7))。
c-Myc还是肿瘤发生和维持的重要介质。c-Myc通过调节多个程序启动和维持肿瘤的发生，包括细胞的DNA复制、生存、死亡、自我更新和能量代谢，在肿瘤微环境(如分泌因子和血管生成的调控)和对免疫应答的影响(Yulin Li J Intern Med.2014 Jul；276(1):52–60.)。c-Myc被抑制后可以逆转肿瘤发生，导致增殖阻滞。此外还发现c-Myc失活可以重构微环境，恢复正常组织结构并阻断血管生成。在多种肿瘤中观察到类似的结果，包括造血(T细胞和B细胞淋巴瘤,白血病)，上皮(肝细胞，乳腺和鳞状细胞癌)和间充质肿瘤(成骨肉瘤)(Felsher DW,Bishop JM Mol Cell.1999 Aug；4(2):199-207.)因此，以c-Myc为抗肿瘤靶标将具有广阔的应用前景。
除癌症外，c-Myc还与一些其他疾病相关。糖尿病是由于β胰岛细胞完全或相对缺失导致的，在糖尿病中，伴随着c-Myc表达的增加，产生胰岛素的β胰岛细胞去分化或者凋亡，其胰岛素的分泌随之下降，这是因为c-Myc缺乏激活胰岛素基因表达的功能，通过与转录因子NeuroD竞争性的集合胰岛素基因启动子的E-box结构而抑制基因的转录和表达(Magid R et al.J Biol Chem,2003,278:32994)。
动脉粥样硬化和血管增生性疾病与肿瘤具有部分相似的病理机制。在动脉粥样硬化产生的单克隆假说中，c-Myc在体内表达增强与主动脉和颈动脉斑块的产生相关，实际上在渡边高血脂兔模型中的早起冠状动脉病变和高胆固醇血症猪的早期冠状动脉血管壁脂质积累中发现了c-Myc依赖性信号通路的激活，更重要的是抗氧化剂以在肿瘤细胞中观察到的类似的方式下调了c-Myc的过表达(Prasad KN et al.Biochem Cell Biol 68,1250-55.)。在动脉发生损伤后再狭窄主要是由于血管细胞增殖引起的并最终导致动脉闭塞。另外，细胞迁移、基质沉积和血管重构也参与了动脉损伤后再狭窄的发生。c-Myc已经被发现与血管平滑肌细胞的增殖至关重要，在球囊发生损伤后，c-Myc的mRNA水平在2小时达到高峰，c-Myc蛋白与DNA结合,促进与细胞增殖的相关基因开放，刺激静止期的平滑肌细胞产生增殖效应，并且c-Myc还能调控血管内皮生长因子VEGFA的表达水平，对血管的新生和成熟产生重要影响(Kokai et al.Circulation Reserach,2009,1151)。
目前，诸多研究证实了c-Myc作为抗肿瘤靶标的临床开发前景，但是目前尚未报道有高活性的c-Myc抑制剂。抗肿瘤药物耐药性问题愈发严重，亟需新型作用机制的药物以满足临床上的巨大需求。本发明公开内容提供了以c-Myc为靶标的强抑制活性化合物。
发明内容
本发明的一个目的是提供一种c-Myc蛋白抑制剂及其制备方法和用途。
一方面，本发明提供式(I)所示的化合物或其药学上可用的盐、溶剂化物、立体异构体和前药：
其中，T选自CHR4,CR4R5；
W为BZ1Z2；
R1选自：RAC(＝O)-、RANHC(＝O)-、RAOC(＝O)-、RACH2C(＝O)-、RAS(＝O)2-或RA；
RA选自：C1-C4烷基、C3-C8环烷基、C3-C8任含O、S、SO2、N或NHC(＝O)R8的杂环基、芳基、杂芳基、芳基-环烷基、芳基-杂环基、环烷基-杂环基、杂环基-杂环基，RA可任选的被一个或多个R6取代；
R2选自：氢、C1-C3烷基、C3-C6环烷基；
R3选自：氢、C1-C6的烷基、C3-C6环烷基、苯基或苄基，所述烷基、环烷基、苯基或者苄基任选1-3个分别选自卤素、氰基、C1-C3烷基或C1-C3烷氧基的基团取代，R3可与R11成C4-C6的环烷基；
R4、R5分别独立的选自：羟基、氨基、R7NHC(＝O)R8、R7C(＝O)OR8、C1-C6的烷基、C1-C6烷氧基、C1-C6烷硫基、C1-C6烷胺基、C3-C8环烷基，芳基、含有1-3个杂原子的5-6元杂芳基或含有1-3个杂原子的3-10元杂环基，所述烷基、烷氧基、烷胺基、烷硫基、环烷基、芳基、杂芳基、杂环基任选的被1-3个分别选自卤素、氰基、C1-C3烷基或C1-C3烷氧基的基团取代，其中R4和R5可以成C3-C6的饱和环或任含O、S、SO2、N或NHC(＝O)R8的饱和杂环；
R6选自：氢、卤素、羟基、氰基、氨基、R7NHC(＝O)R8、R7C(＝O)OR8、C1-C6烷基、C1-C6的烷氧基、C1-C6的烷硫基、C1-C6的烷胺基、C3-C8的环烷基、C2-C8的烯基、C2-C8的炔基、芳基、含有1-3个杂原子的5-6元杂芳基或含有1-3个杂原子的3-10元杂环基，所述烷基、烷氧基、烷胺基、烷硫基、环烷基、芳基、杂芳基、杂环基任选被1-3个分别选自卤素、氰基、C1-C3烷基或C1-C3烷氧基的基团取代；
R7选自：C1-C4的烷基；
R8选自：氢、C1-C4的烷基、烯丙基或苄基；
R11为氢、C1-C3的烷基、C3环烷基；
Z1、Z2分别独立的选自：羟基、C1-C10烷基、C1-C10烷氧基或芳氧基，B、Z1和Z2可一起形成含N、S或O的杂环基。
在一些实施方案中，所述化合物为式(II)所示的化合物或其药学上可用的盐、溶剂化物、立体异构体和前药：
其中T、R1、R2、R3、R11定义同前。
具体的本发明提供以下化合物：
/>
在一些实施方案中，所述化合物为式(III)所示的化合物或其药学上可药用的盐、溶剂化物、立体异构体和前药：
其中T、R1、R2、R3、R11取代基定义同前。
具体的，本发明提供以下具体化合物：
/>
/>
/>
本发明所述的药学上可接受的盐，包括盐酸盐、磷酸盐、磷酸氢盐、磷酸二氢盐、硫酸盐、硝酸盐、碳酸氢盐、碳酸盐、戊二酸盐、氢溴酸盐、醋酸盐、枸橼酸盐、乳酸盐、马来酸盐、苯甲酸盐、甲磺酸盐、草酸盐、苯磺酸盐、对甲苯磺酸盐、酒石酸盐、苹果酸盐、琥珀酸盐、抗坏血酸盐、葡萄糖酸盐、乳酸盐等。
本发明所述溶剂化物选自：半水合物、一水合物、二水合物等；所述立体异构体选自：对应异构体、非对应异构体等。
本发明又一个目的是提供一种药物组合物，所述药物组合物包含药学上可接受的载体和上述化合物或其药学上可用的盐、溶剂化物、立体异构体和前药。
本发明的再一个目的是提供本发明所述化合物或其药学上可用的盐、溶剂化物、立体异构体和前药在制备c-Myc蛋白抑制剂中的用途。
本发明的再一个目的是提供本发明所述化合物或其药学上可用的盐、溶剂化物、立体异构体和前药在制备治疗c-Myc蛋白失调相关疾病中的用途。
优选的，所述c-Myc蛋白失调选自c-Myc蛋白过表达或蛋白稳定性增强。
优选的，所述c-Myc蛋白失调相关疾病选自：癌症、心脑血管疾病、病毒感染相关疾病等。
优选的，所述癌症选自：肝癌、肺癌、肾癌、胰腺癌、口腔癌、胃癌、食道癌、喉癌、鼻咽癌、皮肤癌、乳腺癌、结肠癌、直肠癌、宫颈癌、卵巢癌、前列腺癌、脑癌、神经癌、粒细胞性白血病、横纹肌肉瘤、成骨肉瘤、软骨肉瘤、白血病、淋巴癌等；所述病毒感染相关疾病选自：HIV、乙肝、丙肝、甲肝、流感、流行性乙脑炎、疱疹等。
本发明的有益效果
本发明提供的化合物具有优异的c-Myc蛋白抑制效果，从而可用于c-Myc相关疾病，如癌症、心脑血管疾病、病毒感染等多种疾病的预防和治疗，所述化合物的合成方法简便，c-Myc蛋白抑制效果确切。
附图说明
图1：A5与c-Myc肽LE40单循环结合动力学曲线。
图2：A5与c-Myc肽LE40结合KD为0.16μM。
图3：A5与c-Myc肽LE40(S373A)单循环结合动力学曲线，无明显结合。
图4：化合物A13可以竞争c-Myc与Max的结合。
图5：A5和A13促进c-Myc蛋白的降解。
图6：A13选择性抑制c-Myc高表达的肿瘤细胞。
具体实施方式
下面将结合附图以及进一步的详细说明来举例说明本发明。需要指出的是，以下说明仅仅是对本发明要求保护的技术方案的举例说明，并非对这些技术方案的任何限制。本发明的保护范围以所附权利要求书记载的内容为准。
实施例1
化合物A1
化合物A1是按如下方法合成：
化合物A1-1(2.98g,5mmol)溶于二氯甲烷(DCM)(150mL)中，冰浴下加入1-羟基苯并三唑(HOBt)(810mg,6mmol)和1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDCI)(1.15g,6mmol)。反应30min后，加入A1-2(1.90g,5mmol)和N,N-二异丙基乙胺(DIEA)(1.3mL,7.4mmol)，室温反应两个小时。加水，用DCM萃取(100mL*3)，合并有机相，拉干溶剂后，用中压制备纯化粗产品得到白色固体化合物A1(280mg,产率6.8％)。
1H NMR(400MHz,DMSO)δ8.87(s,1H),8.60(s,1H),7.90(d,J＝7.6Hz,2H),7.78-7.66(m,3H),7.47-7.37(m,2H),7.33(t,J＝7.4Hz,1H),7.20(dt,J＝13.0,6.7Hz,15H),4.44(d,J＝22.6Hz,1H),4.34(d,J＝16.0Hz,1H),4.29-4.15(m,2H),4.08(d,J＝8.4Hz,1H),2.72(t,J＝14.8Hz,1H),2.58(d,J＝6.8Hz,1H),2.46(s,1H),2.24-2.14(m,1H),2.05-1.96(m,1H),1.86-1.79(m,1H),1.80-1.75(m,1H),1.70-1.61(m,2H),1.36-1.20(m,9H),0.84-0.74(m,9H).
ESI-MS(M+H)+:844.
化合物A2-A10合成方法同A1，只需将Fmoc保护的L-天冬酰胺(NH-Trt)换成相应Fmoc保护的氨基酸。
实施例2
化合物A2：
1H NMR(400MHz,DMSO)δ8.67(s,1H),7.88(d,J＝7.3Hz,2H),7.73(t,J＝6.4Hz,2H),7.41(t,J＝7.1Hz,2H),7.31(t,J＝7.2Hz,2H),7.06(d,J＝9.3Hz,1H),4.48-4.28(m,2H),4.24(d,J＝6.2Hz,1H),4.12(dd,J＝18.6,8.5Hz,2H),3.85(t,J＝13.9Hz,1H),2.57(d,J＝21.7Hz,1H),2.18(dd,J＝24.5,14.7Hz,1H),2.01(s,1H),1.81(d,J＝24.2Hz,2H),1.73-1.57(m,2H),1.34(d,J＝9.4Hz,2H),1.26(s,3H),1.21(s,3H),1.10(s,9H),1.03(d,J＝5.7Hz,3H),0.90-0.75(m,9H).
ESI-MS(M+Na)+:667.
实施例3
化合物A3：
1H NMR(400MHz,DMSO)δ8.53(s,1H),7.89(d,J＝7.6Hz,2H),7.72(d,J＝7.7Hz,3H),7.40(t,J＝7.4Hz,2H),7.35-7.29(m,12H),7.25(dt,J＝12.0,4.6Hz,5H),4.33-4.16(m,3H),4.16-4.00(m,2H),2.61(t,J＝9.3Hz,1H),2.39(t,J＝12.8Hz,1H),2.30(dd,J＝11.8,5.5Hz,1H),2.17(dd,J＝17.7,13.3Hz,1H),1.98(dd,J＝13.2,8.4Hz,1H),1.83-1.71(m,2H),1.66-1.53(m,2H),1.33(dd,J＝29.0,15.1Hz,3H),1.17(t,J＝13.8Hz,6H),0.86-0.70(m,9H).
ESI-MS(M+Na)+:855.
实施例4
化合物A4：
1H NMR(400MHz,DMSO)δ8.94(s,1H),7.88(d,J＝7.3Hz,2H),7.66(d,J＝6.0Hz,2H),7.57(d,J＝8.3Hz,1H),7.40-7.38(m,2H),7.36-7.22(m,12H),7.05(d,J＝6.6Hz,6H),6.77(s,1H),4.43(t,J＝10.3Hz,1H),4.29-4.09(m,3H),4.01(d,J＝7.8Hz,1H),2.99-2.74(m,2H),2.66-2.53(m,1H),2.17-2.12(m,1H),1.96(s,1H),1.82-1.51(m,4H),1.41-1.04(m,9H),0.85-0.76(m,9H).
ESI-MS(M+H)+:867.
实施例5
化合物A5：
1H NMR(400MHz,DMSO)δ8.79(s,1H),7.89(d,J＝7.5Hz,2H),7.71(t,J＝7.8Hz,2H),7.64(d,J＝8.1Hz,1H),7.42(t,J＝7.4Hz,2H),7.32(dd,J＝11.7,7.2Hz,2H),4.32-4.14(m,4H),4.10(t,J＝8.3Hz,1H),2.67-2.53(m,1H),2.48-2.40(m,2H),2.22-2.18(m,1H),2.08-2.00(m,4H),1.90-1.74(m,4H),1.70-1.60(m,2H),1.35-1.12(m,9H),0.90-0.72(m,9H).
ESI-MS(M+H)+:619.
实施例6
化合物A6：
1H NMR(400MHz,DMSO)δ8.78(s,1H),8.57(s,1H),7.89(d,J＝7.2Hz,2H),7.71(d,J＝7.1Hz,2H),7.53(d,J＝12.7Hz,1H),7.42(t,J＝7.2Hz,2H),7.37-7.30(m,2H),7.25-7.24(m,6H),7.21-7.15(m,9H),4.30-4.27(m,2H),4.22(d,J＝12.7Hz,1H),4.11-4.04(m,2H),2.20-2.14(m,1H),2.01-1.97(m,1H),1.83-1.76(m,2H),1.77-1.73(m,1H),1.69-1.58(m,2H),1.36-1.16(m,10H),0.85-0.77(m,9H).
ESI-MS(M+H)+:858.
实施例7
化合物A7：
1H NMR(400MHz,DMSO)δ8.72(s,1H),7.89(d,J＝7.5Hz,2H),7.72(t,J＝8.1Hz,2H),7.58(d,J＝8.0Hz,1H),7.42(t,J＝7.4Hz,2H),7.32(t,J＝9.1Hz,2H),4.28-4.20(m,3H),4.17-4.04(m,2H),2.66-2.59(m,1H),2.30-2.14(m,3H),2.04-1.98(m,1H),1.87-1.73(m,4H),1.68-1.61(m,2H),1.39(s,9H),1.34-1.29(m,2H),1.22(d,J＝9.1Hz,6H),0.87-0.74(m,9H).
ESI-MS(M+Na)+:695.
实施例8
化合物A8：
1H NMR(400MHz,DMSO)δ8.95(s,1H),8.03(d,J＝7.6Hz,1H),7.90-7.80(m,3H),7.73(d,J＝7.3Hz,1H),7.67-7.53(m,3H),7.46-7.15(m,6H),4.62-4.39(m,1H),4.20-4.10(m,4H),3.13-2.87(m,2H),2.67-2.50(m,1H),2.30-2.11(m,1H),2.06-1.95(m,1H),1.85-1.72(m,2H),1.70-1.47(m,11H),1.37-1.12(m,9H),0.90-0.68(m,9H).
ESI-MS(M+Na)+:796.
实施例9
化合物A9：
1H NMR(400MHz,DMSO)δ8.81(s,1H),8.60(s,1H),7.90(d,J＝7.6Hz,2H),7.82-7.70(m,2H),7.42(dd,J＝15.8,7.9Hz,2H),7.34(d,J＝7.3Hz,1H),7.28-7.06(m,17H),4.47-4.30(m,2H),4.25-4.18(m,2H),4.12-4.08(m,1H),2.80-2.64(m,1H),2.62-2.52(m,1H),2.25-2.16(m,1H),2.03-2.00(m,1H),1.86-1.73(m,2H),1.67-1.60(m,2H),1.45-1.18(m,9H),0.84-0.72(m,9H).
ESI-MS(M+H)+:844.
实施例10
化合物A10：
/>
1H NMR(400MHz,DMSO)δ8.98(s,1H),7.90(d,J＝7.5Hz,2H),7.71(t,J＝7.6Hz,2H),7.61(d,J＝8.4Hz,1H),7.42(t,J＝7.4Hz,2H),7.33(q,J＝7.0Hz,2H),4.29(d,J＝7.1Hz,2H),4.24-4.12(m,2H),4.06(d,J＝7.0Hz,1H),2.31-2.10(m,1H),2.10-1.88(m,1H),1.88-1.63(m,4H),1.63-1.33(m,4H),1.33-1.17(m,9H),0.94-0.75(m,13H).
ESI-MS(M+Na)+:623.
实施例11
化合物A11
是按如下方法合成：
1.中间体A11-1的合成
L-苏氨酸(119mg,1mmol)和碳酸钠(159mg,1.5mmol)溶于1,4-二氧六环(3mL)和水(2mL)中，慢慢加入9-芴甲基-N-琥珀酰亚胺基碳酸酯(337mg,1mmol)的1,4-二氧六环(3mL)溶液。室温反应6h。薄层色谱(TLC)显示原料完全反应完。拉干溶剂，加稀盐酸调节pH值到3-4，有固体析出，过滤，将滤饼用乙酸乙酯洗下来，无水硫酸钠干燥，过滤，拉干，得到白色固体化合物A11-1(280mg,产率82％)。
2.化合物A11的合成
化合物A11-1(170mg,0.5mmol)和A1-2(227mg,0.6mmol)溶于DCM(3mL)中，加入2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(HATU)(285mg,0.75mmol)和三乙胺(TEA)(151mg,1.5mmol)，室温反应两个小时。加水，用DCM萃取(15mL*3)，合并有机相，拉干溶剂后，用中压制备纯化粗产品得到白色固体化合物A11(20mg,产率6.8％)。
1H NMR(400MHz,DMSO)δ8.88(s,1H),7.90(d,J＝7.5Hz,2H),7.75(t,J＝8.2Hz,2H),7.53(d,J＝9.1Hz,1H),7.43(t,J＝7.4Hz,2H),7.34(dd,J＝12.8,6.6Hz,2H),4.94(d,J＝5.2Hz,1H),4.29(d,J＝7.1Hz,2H),4.24(d,J＝5.9Hz,1H),4.09(t,J＝8.3Hz,2H),3.88(dd,J＝11.6,6.2Hz,1H),3.61(t,J＝6.6Hz,2H),2.18(d,J＝8.9Hz,1H),2.00(d,J＝7.3Hz,2H),1.84(t,J＝5.5Hz,1H),1.80-1.75(m,2H),1.36(s,2H),1.34-1.29(m,2H),1.25(d,J＝9.3Hz,7H),1.22(s,4H),1.07(d,J＝6.2Hz,3H),0.85(d,J＝6.4Hz,6H),0.81(s,3H).
ESI-MS(M+H)+:589.
化合物A12-A18合成方法同A11，只需将L-苏氨酸换成相应的氨基酸。
实施例12
化合物A12：
1H NMR(400MHz,DMSO)δ8.83(s,1H),7.90(d,J＝7.5Hz,2H),7.72(t,J＝8.1Hz,2H),7.64(d,J＝7.7Hz,1H),7.43(t,J＝7.4Hz,2H),7.33(td,J＝7.3,3.6Hz,2H),4.39-4.11(m,4H),4.07(d,J＝6.6Hz,1H),2.57(s,1H),2.26-2.14(m,1H),2.01(dd,J＝14.9,7.1Hz,2H),1.82(t,J＝5.6Hz,1H),1.76(s,1H),1.71-1.53(m,2H),1.40-1.15(m,14H),0.84(d,J＝6.5Hz,6H),0.80(s,3H).
ESI-MS(M+H)+:573.
实施例13
化合物A13：
1H NMR(400MHz,DMSO)δ8.90(s,1H),7.90(d,J＝7.5Hz,2H),7.71(t,J＝7.5Hz,2H),7.58(d,J＝8.1Hz,1H),7.42(t,J＝7.4Hz,2H),7.33(dd,J＝12.4,7.1Hz,2H),6.76(s,1H),4.34-4.16(m,3H),4.07(d,J＝8.1Hz,2H),2.89(d,J＝5.8Hz,2H),2.56(s,1H),2.25-2.13(m,1H),2.04(d,J＝32.9Hz,2H),1.81(dd,J＝16.8,11.2Hz,2H),1.72-1.52(m,5H),1.36(d,J＝11.2Hz,13H),1.22(d,J＝6.1Hz,11H),0.84(d,J＝6.4Hz,7H),0.80(s,3H).
ESI-MS(M+H)+:716.
实施例14
化合物A14：
1H NMR(400MHz,DMSO)δ8.73(s,1H),7.90(d,J＝7.5Hz,2H),7.72(t,J＝7.8Hz,2H),7.61(d,J＝8.2Hz,1H),7.43(t,J＝7.4Hz,2H),7.33(td,J＝7.3,3.4Hz,2H),4.28(d,J＝6.8Hz,2H),4.25-4.17(m,1H),4.13(t,J＝8.5Hz,2H),3.60(s,3H),2.66(d,J＝17.5Hz,2H),2.34(t,J＝14.6Hz,2H),2.29-2.15(m,1H),2.10-1.97(m,2H),1.94-1.74(m,4H),1.73-1.58(m,2H),1.37-1.17(m,11H),0.93-0.72(m,9H).
ESI-MS(M+H)+:645.
实施例15
化合物A15：
1H NMR(400MHz,DMSO)δ8.89(d,J＝2.8Hz,1H),7.89(d,J＝7.5Hz,2H),7.75(d,J＝8.6Hz,2H),7.64(d,J＝7.5Hz,2H),7.41(t,J＝7.5Hz,2H),7.29(td,J＝14.9,7.6Hz,5H),4.36(dd,J＝14.1,9.1Hz,1H),4.28-4.14(m,4H),3.05-2.98(m,2H),2.01(d,J＝15.3Hz,2H),1.83(dd,J＝18.6,13.1Hz,2H),1.39-1.23(m,9H),0.83(dd,J＝12.8,6.1Hz,8H).
ESI-MS(M+H)+:635.
实施例16
化合物A16：
/>
1H NMR(400MHz,DMSO)δ8.64(s,1H),7.89(d,J＝7.5Hz,2H),7.70(d,J＝8.0Hz,3H),7.42(t,J＝7.4Hz,2H),7.33(t,J＝7.5Hz,2H),4.48(dd,J＝13.9,8.4Hz,1H),4.34-4.19(m,3H),4.14-4.09(m,1H),3.59(s,3H),2.66(dd,J＝11.0,6.2Hz,2H),2.25-2.15(m,1H),2.00(dd,J＝14.1,6.6Hz,2H),1.84(t,J＝5.6Hz,1H),1.77(s,1H),1.64(t,J＝12.7Hz,2H),1.30-1.22(m,9H),0.85-0.76(m,9H).
ESI-MS(M+Na)+:639.
实施例17
化合物A17：
1H NMR(400MHz,DMSO)δ8.87(d,J＝2.8Hz,1H),7.90(d,J＝7.5Hz,2H),7.74(t,J＝8.6Hz,3H),7.42(t,J＝7.4Hz,2H),7.37-7.27(m,4H),7.19(t,J＝7.6Hz,3H),4.32(d,J＝7.0Hz,2H),4.24(t,J＝7.0Hz,1H),4.10(dd,J＝12.9,7.1Hz,2H),2.68-2.54(m,3H),2.19(d,J＝2.3Hz,1H),2.08(s,1H),2.05-1.96(m,1H),1.88(dd,J＝15.4,7.9Hz,2H),1.82(t,J＝5.6Hz,1H),1.76(s,1H),1.71-1.59(m,2H),1.32(dd,J＝15.2,6.2Hz,2H),1.23(s,3H),1.20(s,3H),0.84(d,J＝6.5Hz,6H),0.79(s,3H).
ESI-MS(M+H)+:649.
实施例18
化合物A18：
1H NMR(400MHz,DMSO)δ10.87(s,1H),9.05(s,1H),7.86(d,J＝7.6Hz,2H),7.63(dd,J＝15.2,7.7Hz,4H),7.38(dd,J＝13.1,6.9Hz,2H),7.31(d,J＝8.8Hz,2H),7.25(dd,J＝14.5,6.7Hz,1H),7.17(s,1H),7.05(t,J＝7.2Hz,1H),6.97(t,J＝7.3Hz,1H),4.39(d,J＝5.8Hz,1H),4.19-4.05(m,4H),3.08-2.93(m,2H),2.52(s,1H),2.16(s,2H),2.06-1.90(m,2H),1.81(dd,J＝18.0,12.2Hz,2H),1.64(d,J＝14.8Hz,2H),1.30-1.20(m,7H),0.88-0.73(m,9H).
ESI-MS(M+H)+:674.
实施例19
化合物A19：
化合物A19是按如下方法合成的：
将N2-boc-N4-Trt-L-天冬酰胺(200mg,0.42mmol)溶于二氯甲烷(10mL)中，向其中依次加入1-丙基磷酸酐(T3P)(50％wt，乙酸乙酯(EtOAc),1.2mL),A1-2(135mg,0.51mmol)和TEA(1.2mL)。常温反应3h后，加水(30mL)稀释。有机相用二氯甲烷萃取(20mL*3)后合并干燥旋干。溶质用中压制备纯化，得白色固体(100mg,33％产率)。
1H NMR(400MHz,DMSO)δ8.85(s,1H),8.60(s,1H),7.23(dt,J＝13.5,7.8Hz,15H),7.13(d,J＝8.4Hz,1H),4.39-4.27(m,1H),4.07(d,J＝7.2Hz,1H),2.67(dd,J＝14.2,10.4Hz,1H),2.53(d,J＝9.5Hz,1H),2.43(dd,J＝14.6,4.0Hz,1H),2.20(dd,J＝21.4,10.0Hz,1H),2.09-1.95(m,3H),1.83(t,J＝5.5Hz,1H),1.79(d,J＝5.4Hz,1H),1.66(dd,J＝18.1,10.3Hz,2H),1.34(dd,J＝12.2,7.8Hz,6H),1.31-1.16(m,10H),0.89-0.75(m,9H).
ESI-MS(M-H)-:720.
化合物A20-A21合成方法同A19，只需将原料N2-boc-N4-Trt-L-天冬酰胺换成N2-Cbz-N4-Trt-L-天冬酰胺和Cbz-L-色氨酸。
实施例20
化合物A20：
1H NMR(400MHz,DMSO)δ8.91(s,1H),8.76(d,J＝12.1Hz,2H),7.64(d,J＝8.3Hz,1H),7.49-7.34(m,5H),7.30(s,2H),7.25-7.01(m,14H),5.12-5.01(m,2H),4.11(dd,J＝12.5,7.2Hz,3H),2.70(dd,J＝14.6,10.4Hz,1H),2.51(dt,J＝3.6,1.8Hz,5H),2.25-2.16(m,1H),1.98(m,1H),1.74(m,2H),1.16(m,9H),0.85(dd,J＝20.2,13.6Hz,9H).
ESI-MS(M+H)+:844.
实施例21
化合物A21
1H NMR(400MHz,DMSO)δ10.89(s,1H),9.09(s,1H),7.59(dd,J＝23.8,8.1Hz,2H),7.37-7.29(m,3H),7.28-7.22(m,2H),7.17(d,J＝2.2Hz,1H),7.07(t,J＝7.5Hz,1H),6.99(t,J＝7.2Hz,1H),4.96(q,J＝12.7Hz,2H),4.45-4.34(m,1H),4.11(d,J＝7.0Hz,1H),3.10-3.02(m,1H),2.98(dd,J＝14.4,9.1Hz,1H),2.55(d,J＝8.5Hz,1H),2.29-2.18(m,1H),2.07-1.97(m,1H),1.85(dd,J＝18.0,12.3Hz,2H),1.64(dd,J＝19.1,10.5Hz,2H),1.38(d,J＝10.0Hz,1H),1.29(s,3H),1.22(d,J＝12.5Hz,6H),0.84(t,J＝6.0Hz,8H).
ESI-MS(M+H)+:586.
实施例22
化合物A22
化合物A22是按如下方法合成的：
1.中间体A22-1的合成：
L-亮氨酸(131mg,1mmol)和碳酸钠(159mg,1.5mmol)溶于1,4-二氧六环(3mL)和水(2mL)中，慢慢加入9-芴甲基-N-琥珀酰亚胺基碳酸酯(337mg,1mmol)的1,4-二氧六环(3mL)溶液。室温反应6h。TLC显示原料完全反应完。拉干溶剂，加稀盐酸调节pH值到3-4，有固体析出，过滤，将滤饼用乙酸乙酯洗下来，无水硫酸钠干燥，过滤，拉干，得到白色固体化合物A22-1(250mg,产率71％)。
1.化合物A22的合成
化合物A87-1(176mg,0.5mmol)和化合物A22-2(227mg,0.6mmol)溶于DCM(3mL)中，加入HATU(285mg,0.75mmol)和TEA(151mg,1.5mmol)，室温反应两个小时。加水，用DCM萃取(15mL*3)，合并有机相，拉干溶剂后，用中压制备纯化粗产品得到白色固体化合物A22(18mg,产率6.4％)。
1H NMR(400MHz,DMSO)δ9.11(s,1H),7.89(d,J＝7.5Hz,2H),7.71(t,J＝7.7Hz,2H),7.64(d,J＝8.3Hz,1H),7.41(t,J＝7.4Hz,2H),7.32(dt,J＝14.2,7.0Hz,2H),4.36-4.24(m,2H),4.21(t,J＝6.9Hz,1H),4.13(td,J＝9.7,5.1Hz,1H),4.04(d,J＝6.9Hz,1H),2.57-2.51(m,1H),2.18(dd,J＝12.2,9.9Hz,1H),2.05-1.92(m,1H),1.81(t,J＝5.6Hz,1H),1.77(d,J＝5.2Hz,1H),1.68-1.56(m,2H),1.56-1.48(m,1H),1.40(ddd,J＝21.4,10.7,6.3Hz,1H),1.33(d,J＝10.0Hz,1H),1.23(t,J＝7.2Hz,9H),1.00(d,J＝7.2Hz,3H),0.89(d,J＝6.5Hz,3H),0.84(d,J＝6.4Hz,4H),0.79(s,3H).
ESI-MS(M+H)+:601.
化合物A23合成方法同A22，只需将L-亮氨酸换成Boc-L-赖氨酸。
实施例23
化合物A23：
1H NMR(400MHz,DMSO)δ9.04(s,1H),7.90(d,J＝7.5Hz,2H),7.72(t,J＝7.5Hz,2H),7.62(d,J＝8.0Hz,1H),7.42(t,J＝7.4Hz,2H),7.33(dd,J＝12.4,7.1Hz,2H),6.76(s,1H),4.26(dd,J＝23.9,6.5Hz,3H),4.05(d,J＝8.4Hz,2H),2.89(d,J＝6.0Hz,2H),2.55(s,1H),2.25-2.14(m,1H),2.06-1.95(m,1H),1.83(t,J＝5.5Hz,1H),1.77(s,1H),1.69-1.48(m,3H),1.37(s,13H),1.23(d,J＝7.6Hz,9H),1.01(d,J＝7.2Hz,3H),0.80(s,3H).
ESI-MS(M+H)+:674.
实施例24
化合物A24
化合物A24是按如下方法合成的：
1.中间体A24-1的合成
9-芴乙酸(224mg,1mmol)和L-亮氨酸乙酯(286mg,1.8mmol)溶于DCM(4mL)中，加入2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(HATU)(760mg,2mmol)和TEA(350mg,3.5mmol)，室温反应两个小时。加水，用DCM萃取(20mL*3)，合并有机相，拉干溶剂后，用厚制备板纯化得到白色固体化合物A24-1(145mg,产率40％)。
2.中间体A24-2的合成
化合物A24-1(145mg,0.4mmol)溶于甲醇(MeOH)(4mL)，低温下加入氢氧化锂(LiOH)(1mL,1M)水溶液，室温下反应2h。TLC显示原料反应完全，拉干溶剂，加稀盐酸调pH至3-4，用乙酸乙酯萃取(10mL*3)，合并有机相，拉干溶剂，得到化合物A24-2(102mg,产率75.6％)。
3.化合物A24的合成
化合物A24-2(100mg,0.3mmol)和化合物A1-2(170mg,0.45mmol)溶于DCM(3mL)中，加入HATU(228mg,0.6mmol)和TEA(120mg,1.2mmol)，室温反应两个小时。加水，用DCM萃取(15mL*3)，合并有机相，拉干溶剂后，用中压制备纯化粗产品得到白色固体化合物A24(25mg,产率14.3％)。
1H NMR(400MHz,DMSO)δ9.06(d,J＝2.5Hz,1H),8.24(d,J＝8.0Hz,1H),7.86(d,J＝7.5Hz,2H),7.54(d,J＝7.4Hz,1H),7.49(d,J＝7.5Hz,1H),7.38(t,J＝7.4Hz,2H),7.33-7.22(m,2H),4.65-4.55(m,1H),4.36(t,J＝7.5Hz,1H),4.08(dd,J＝8.5,1.7Hz,1H),2.69(dd,J＝14.8,6.9Hz,1H),2.59(dd,J＝10.6,4.6Hz,1H),2.47(d,J＝8.3Hz,1H),2.26-2.14(m,1H),2.07-1.96(m,1H),1.85(t,J＝5.6Hz,1H),1.81-1.69(m,2H),1.68-1.56(m,2H),1.55-1.38(m,2H),1.38-1.26(m,3H),1.24(d,J＝12.3Hz,6H),0.89(dd,J＝15.5,6.6Hz,12H),0.81(s,3H).
ESI-MS(M+H)+:584.
化合物A25-A38合成方法同A24，只需将第一步的原料9-芴乙酸和L-亮氨酸乙酯换成相应的酸以及氨基酸酯。
实施例25
化合物A25：
1H NMR(400MHz,DMSO)δ10.85(s,1H),9.03(s,1H),7.92(dd,J＝45.2,8.1Hz,1H),7.60(d,J＝7.7Hz,1H),7.31(d,J＝8.0Hz,1H),7.20–7.12(m,1H),7.05(t,J＝7.5Hz,1H),6.98(t,J＝7.4Hz,1H),4.69(dt,J＝16.4,8.3Hz,1H),4.18-4.01(m,1H),3.12-3.00(m,1H),2.99-2.88(m,1H),2.28-2.16(m,1H),2.02(d,J＝6.6Hz,1H),1.90-1.84(m,1H),1.80(s,6H),1.71-1.61(m,2H),1.61(s,3H),1.45(d,J＝11.6Hz,3H),1.38(s,6H),1.30(d,J＝13.2Hz,4H),1.23(s,6H),0.83(d,J＝5.2Hz,9H).
ESI-MS(M+H)+:628.
实施例26
化合物A26：
1H NMR(400MHz,DMSO)δ10.85(d,J＝5.3Hz,1H),8.78(d,J＝3.0Hz,1H),7.66-7.55(m,1H),7.31(d,J＝7.9Hz,2H),7.16(d,J＝2.2Hz,1H),7.06(s,1H),6.98(s,1H),4.72-4.53(m,1H),4.17-4.03(m,1H),3.19-2.96(m,2H),2.30-2.14(m,1H),2.10-1.98(m,1H),1.91(s,5H),1.62(dd,J＝25.6,13.3Hz,14H),1.29(d,J＝6.2Hz,3H),1.24(d,J＝2.7Hz,4H),0.90-0.78(m,9H).
ESI-MS(M+H)+:614.
实施例27
化合物A27：
1H NMR(400MHz,DMSO)δ8.89(dd,J＝77.4,3.0Hz,1H),8.03(d,J＝8.1Hz,1H),7.92(d,J＝8.3Hz,1H),7.69(d,J＝7.6Hz,1H),7.51(s,1H),7.29(dt,J＝26.5,7.3Hz,2H),5.99(dt,J＝5.9,3.0Hz,1H),5.74(ddd,J＝20.9,5.5,2.7Hz,1H),4.64(d,J＝6.5Hz,1H),4.20-4.02(m,1H),3.16(d,J＝14.3Hz,1H),3.08-2.89(m,2H),2.80(dd,J＝11.2,5.3Hz,2H),2.28-2.14(m,1H),2.02(dd,J＝14.2,6.7Hz,1H),1.90-1.76(m,2H),1.73-1.54(m,11H),1.39-1.26(m,5H),1.29-1.09(m,9H),0.92-0.72(m,9H).
ESI-MS(M+H)+:672.
实施例28
化合物A28：
1H NMR(400MHz,DMSO)δ8.99(d,J＝2.9Hz,1H),8.04(d,J＝8.1Hz,1H),7.79(d,J＝8.5Hz,1H),7.71(d,J＝7.6Hz,1H),7.53(s,1H),7.29(dt,J＝24.3,7.0Hz,2H),4.69(dd,J＝14.9,8.5Hz,1H),4.12(t,J＝12.1Hz,1H),3.04(s,2H),2.59-2.53(m,1H),2.38(s,2H),2.22(dd,J＝12.3,9.9Hz,1H),2.09-1.76(m,16H),1.61(s,9H),1.25(d,J＝18.9Hz,9H),0.86-0.80(m,9H).
ESI-MS(M+H)+:728.
实施例29
化合物A29：
1H NMR(400MHz,DMSO)δ10.87(d,J＝1.7Hz,1H),9.09(s,1H),8.02(d,J＝8.2Hz,1H),7.60(d,J＝7.8Hz,1H),7.32(d,J＝8.0Hz,1H),7.16(d,J＝2.2Hz,1H),7.06(dd,J＝11.1,4.0Hz,1H),6.99(dd,J＝10.9,3.9Hz,1H),4.66(td,J＝8.6,5.5Hz,1H),4.08(dd,J＝8.5,1.8Hz,1H),3.00(ddd,J＝23.6,14.5,7.2Hz,2H),2.26-2.19(m,1H),2.08-1.97(m,1H),1.94-1.88(m,2H),1.86(dd,J＝11.4,6.2Hz,1H),1.83-1.78(m,2H),1.69-1.48(m,5H),1.37(d,J＝7.9Hz,4H),1.29(d,J＝6.2Hz,3H),1.25-1.18(m,6H),1.15-0.99(m,4H),0.82(dd,J＝13.3,8.8Hz,9H).
ESI-MS(M+H)+:576.
实施例30
化合物A30
1H NMR(400MHz,DMSO)δ10.86(s,1H),9.07(s,1H),8.00(d,J＝8.2Hz,1H),7.59(d,J＝7.8Hz,1H),7.31(d,J＝8.0Hz,1H),7.15(d,J＝2.2Hz,1H),7.05(t,J＝7.1Hz,1H),6.98(t,J＝7.4Hz,1H),4.70-4.59(m,1H),4.13-4.03(m,1H),3.00(ddd,J＝23.5,14.6,7.2Hz,2H),2.27-2.14(m,1H),2.00(dd,J＝9.2,5.0Hz,4H),1.84(t,J＝5.6Hz,1H),1.80(d,J＝5.2Hz,1H),1.70-1.34(m,10H),1.27-1.16(m,10H),1.10-0.92(m,2H),0.82(dd,J＝4.5,1.7Hz,9H).
ESI-MS(M+Na)+:561.56.
实施例31
化合物A31
1H NMR(400MHz,DMSO)δ10.83(s,1H),9.02-8.90(m,1H),7.98-7.83(m,1H),7.55(d,J＝7.8Hz,1H),7.28(d,J＝8.0Hz,1H),7.11(d,J＝2.4Hz,1H),7.02(t,J＝7.5Hz,1H),6.94(t,J＝7.4Hz,1H),4.60(dt,J＝10.4,6.7Hz,1H),4.06(d,J＝6.7Hz,1H),3.09-2.97(m,1H),2.97-2.84(m,1H),2.23-2.12(m,1H),1.98(dd,J＝14.5,6.8Hz,2H),1.86-1.73(m,2H),1.67-1.48(m,2H),1.29-1.10(m,9H),0.83-0.76(m,9H).
ESI-MS(M+H)+:534.
实施例32
化合物A32
1H NMR(400MHz,DMSO)δ10.92(s,1H),8.91(d,J＝3.3Hz,1H),7.70(d,J＝8.6Hz,1H),7.60(d,J＝7.7Hz,1H),7.39-7.26(m,4H),7.19(dd,J＝7.7,2.2Hz,3H),7.11-6.97(m,2H),4.18(ddd,J＝39.6,24.2,10.7Hz,3H),3.91(d,J＝13.7Hz,1H),3.03(ddd,J＝22.1,14.4,7.2Hz,2H),2.59(d,J＝9.3Hz,1H),2.26-2.17(m,1H),2.07-1.99(m,1H),1.83(dd,J＝15.4,9.6Hz,2H),1.67(d,J＝13.9Hz,1H),1.51-1.44(m,1H),1.36(d,J＝10.2Hz,1H),1.28(s,3H),1.26-1.20(m,5H),1.20-1.16(m,1H),0.79(dd,J＝6.7,3.5Hz,9H).
ESI-MS(M+H)+:606.
实施例33
化合物A33
1H NMR(400MHz,DMSO)δ10.83(s,1H),9.11(d,J＝2.9Hz,1H),8.92(d,J＝8.2Hz,1H),8.70(dd,J＝4.5,1.5Hz,2H),7.75-7.63(m,3H),7.30(d,J＝8.0Hz,1H),7.22(d,J＝2.2Hz,1H),7.05(t,J＝7.0Hz,1H),6.98(t,J＝7.4Hz,1H),4.89–4.78(m,1H),4.12(d,J＝6.7Hz,1H),3.24–3.12(m,2H),2.59(t,J＝7.7Hz,1H),2.27–2.15(m,1H),2.06–1.98(m,1H),1.83(dd,J＝17.2,11.5Hz,2H),1.63(dd,J＝13.3,7.7Hz,2H),1.32(dd,J＝18.5,9.1Hz,3H),1.26(s,3H),1.22(s,4H),0.88–0.75(m,9H).
ESI-MS(M+H)+:557.
实施例34
化合物A34
1H NMR(400MHz,DMSO)δ10.86(s,1H),8.94(dd,J＝23.9,6.0Hz,2H),8.28-8.07(m,2H),7.72-7.52(m,3H),7.31(d,J＝8.1Hz,1H),7.21(d,J＝2.1Hz,1H),7.05(t,J＝7.5Hz,1H),6.96(t,J＝7.4Hz,1H),4.86(dt,J＝13.5,6.8Hz,1H),4.18(d,J＝8.6Hz,1H),3.32-3.23(m,2H),2.69(d,J＝3.6Hz,1H),2.29-2.19(m,1H),2.03(dd,J＝17.1,8.9Hz,1H),1.87(t,J＝5.6Hz,1H),1.80(s,1H),1.65(t,J＝12.8Hz,2H),1.37-1.21(m,10H),0.90-0.76(m,8H).
ESI-MS(M+H)+:613.
实施例35
化合物A35
1H NMR(400MHz,DMSO)δ10.85(s,1H),9.20-9.11(m,1H),8.99(dd,J＝4.2,1.6Hz,1H),8.86(t,J＝9.5Hz,1H),8.50-8.41(m,2H),8.19-8.10(m,1H),8.06(dd,J＝8.8,3.1Hz,1H),7.71(d,J＝7.7Hz,1H),7.62(dd,J＝8.3,4.2Hz,1H),7.29(dd,J＝19.5,5.1Hz,2H),7.10-6.96(m,2H),4.93(dd,J＝14.7,7.9Hz,1H),4.12(d,J＝6.6Hz,1H),3.27-3.15(m,2H),2.60(t,J＝6.1Hz,1H),2.30-2.17(m,1H),2.05(t,J＝11.3Hz,1H),1.92-1.77(m,2H),1.69-1.57(m,2H),1.34-1.19(m,9H),0.89-0.77(m,9H).
ESI-MS(M+H)+:607.
实施例36
化合物A36
1H NMR(400MHz,DMSO)δ10.86(s,1H),9.30-9.09(m,2H),9.02(dd,J＝20.6,8.2Hz,1H),8.78(dd,J＝13.2,2.0Hz,1H),8.07(t,J＝7.9Hz,2H),7.88(t,J＝7.7Hz,1H),7.71(t,J＝7.6Hz,2H),7.37-7.23(m,2H),7.11-6.95(m,2H),4.93(dd,J＝8.6,5.4Hz,1H),4.14(t,J＝6.4Hz,1H),3.24(ddd,J＝15.1,9.6,5.4Hz,2H),2.60(t,J＝6.5Hz,1H),2.23(s,1H),2.02(d,J＝6.1Hz,1H),1.90-1.77(m,2H),1.75-1.60(m,2H),1.39(t,J＝10.2Hz,1H),1.35-1.29(m,2H),1.30-1.17(m,7H),0.84(ddd,J＝10.5,6.9,4.5Hz,8H).
ESI-MS(M+H)+:607.
实施例37
化合物A37
1H NMR(400MHz,DMSO)δ10.86(s,1H),9.23-9.12(m,1H),8.77(dd,J＝19.8,8.2Hz,1H),8.42(d,J＝14.0Hz,1H),8.04-7.94(m,3H),7.89(ddd,J＝12.6,8.6,1.6Hz,1H),7.72(d,J＝7.7Hz,1H),7.66-7.56(m,2H),7.36-7.25(m,2H),7.04(dt,J＝14.8,6.9Hz,2H),4.97-4.82(m,1H),4.18-4.06(m,1H),3.25(t,J＝6.5Hz,2H),2.59(d,J＝7.1Hz,1H),2.29-2.17(m,1H),2.04-1.98(m,1H),1.91-1.76(m,2H),1.73-1.60(m,2H),1.37(dd,J＝22.5,12.6Hz,3H),1.29-1.21(m,7H),0.84(ddd,J＝11.4,7.0,4.0Hz,9H).
ESI-MS(M+H)+:606.
实施例38
化合物A38
1H NMR(400MHz,DMSO)δ8.84(t,J＝19.4Hz,1H),8.30(dd,J＝23.1,7.9Hz,1H),7.86(d,J＝7.5Hz,2H),7.54(t,J＝8.1Hz,2H),7.33(dtd,J＝25.0,7.3,2.7Hz,5H),6.97(s,1H),4.90(dd,J＝13.1,8.1Hz,1H),4.33(t,J＝7.3Hz,1H),4.10(d,J＝6.7Hz,1H),2.63(dd,J＝14.7,7.0Hz,2H),2.57-2.51(m,1H),2.49-2.40(m,2H),2.25-2.16(m,1H),2.00(dd,J＝14.8,6.9Hz,1H),1.86(t,J＝5.6Hz,1H),1.79(s,1H),1.72(dd,J＝13.6,6.9Hz,1H),1.64(d,J＝13.6Hz,1H),1.38-1.28(m,3H),1.23(s,5H),0.84(dd,J＝17.2,8.0Hz,10H).
ESI-MS(M+Na)+:608.2.
实施例39
化合物A39
化合物A39是按如下方法合成的：
1.中间体A39-1的合成
9H-吡啶并[3,4-b]吲哚(3g,18mmol)溶于N,N-二甲基甲酰胺(DMF)(25mL)中，低温下加入氢氧化钾固体(3g,54mmol)，室温反应1h。加入溴乙酸乙酯(7.4g,45mmol)后，室温反应16h。TLC显示原料反应完全，加水后用乙酸乙酯萃取(80mL*3)，合并有机相，拉干溶剂，得到黄色固体化合物A39-1(1g,产率22％)。
2.中间体A39-2的合成
A39-1(1g,4mmol)溶于MeOH(15mL)，低温下加入LiOH(6mL,1M)水溶液，室温下反应2h。TLC显示原料反应完全，拉干溶剂，加稀盐酸调pH至3-4，用乙酸乙酯萃取(15mL*3)，合并有机相，拉干溶剂，得到化合物A39-2(790mg,产率88％)。
3.中间体A39-3的合成
A39-2(225mg,1mmol)和L-亮氨酸乙酯(353mg,1.8mmol)溶于DCM(4mL)中，加入HATU(760mg,2mmol)和TEA(350mg,3.5mmol)，室温反应两个小时。加水，用DCM萃取(20mL*3)，合并有机相，拉干溶剂后，用厚制备板纯化得到白色固体化合物A39-3(160mg,产率44％)。
4.中间体A39-4的合成
A39-3(160mg,0.44mmol)溶于MeOH(4mL)，低温下加入LiOH(1mL,1M)水溶液，室温下反应2h。TLC显示原料反应完全，拉干溶剂，加稀盐酸调pH至3-4，用乙酸乙酯萃取(10mL*3)，合并有机相，拉干溶剂，得到化合物A39-4(110mg,产率74％)。
5.化合物A39的合成
A39-4(100mg,0.3mmol)和A1-2(170mg,0.45mmol)溶于DCM(3mL)中，加入HATU(230mg,0.6mmol)和TEA(120mg,1.2mmol)，室温反应两个小时。加水，用DCM萃取(15mL*3)，合并有机相，拉干溶剂后，用中压制备纯化粗产品得到白色固体化合物A39(12mg,产率6.8％)。
1H NMR(400MHz,DMSO)δ9.01(s,1H),8.96(s,1H),8.78(d,J＝8.3Hz,1H),8.38(d,J＝5.2Hz,1H),8.30-8.24(m,2H),8.13(d,J＝5.2Hz,1H),7.65-7.53(m,2H),7.29(t,J＝7.3Hz,1H),5.22(q,J＝16.9Hz,2H),4.43(dd,J＝14.3,8.9Hz,1H),4.10(d,J＝6.7Hz,1H),2.55(d,J＝8.8Hz,1H),2.27-2.16(m,1H),2.08-1.95(m,2H),1.85(t,J＝5.6Hz,1H),1.81(d,J＝5.5Hz,1H),1.65(dd,J＝16.6,9.4Hz,4H),1.58-1.40(m,3H),1.33(d,J＝10.1Hz,1H),1.28(s,4H),1.22(d,J＝9.9Hz,6H),0.93-0.89(m,3H),0.83(dd,J＝9.6,4.4Hz,12H).
ESI-MS(M+H)+:545.
化合物A40-A41合成方法同A39，只需将第一步的9H-吡啶并[3,4-b]吲哚换成相应的胺。
实施例40
化合物A40：
1H NMR(400MHz,DMSO)δ8.92(d,J＝2.9Hz,1H),8.63(d,J＝8.1Hz,1H),8.48(d,J＝1.8Hz,2H),7.57(dt,J＝18.6,5.3Hz,4H),5.11(d,J＝19.7Hz,2H),4.41(dd,J＝14.4,8.8Hz,1H),4.10(d,J＝6.8Hz,1H),1.86(s,2H),1.64(d,J＝13.7Hz,5H),1.39-1.25(m,7H),1.23(d,J＝9.3Hz,5H),0.91(d,J＝6.6Hz,3H),0.88-0.75(m,12H).
ESI-MS(M+H)+:744.
实施例41
化合物A41：
1H NMR(400MHz,DMSO)δ8.96(s,1H),8.73(d,J＝7.9Hz,1H),8.35(dd,J＝8.0,1.5Hz,2H),7.77(t,J＝7.0Hz,2H),7.61(s,2H),7.35(s,2H),5.24(s,2H),4.52-4.43(m,1H),4.12(d,J＝6.8Hz,1H),2.58(s,1H),2.22(d,J＝11.3Hz,1H),2.01(dd,J＝14.4,7.0Hz,3H),1.87(t,J＝5.6Hz,1H),1.83(d,J＝6.2Hz,1H),1.66(d,J＝13.8Hz,3H),1.59-1.44(m,3H),1.35-1.25(m,6H),0.93(d,J＝6.6Hz,3H),0.85(dd,J＝6.5,4.0Hz,12H).ESI-MS(M+H)+:614.
实施例42
化合物A42
化合物A42是如下方法合成的：
1.中间体A42-1的合成
将9-氨基芴盐酸盐(1g,4.60mmol)溶于20mL二氯甲烷中，冰浴下向其中依次加入三乙胺(1.91mL)和三光气(550mg,1.85mmol)。搅拌30min后，向其中加入L-亮氨酸乙酯(920mg,5.04mmol)。常温反应1h后，加水(10mL)淬灭反应。用二氯甲烷萃取(20mL*3)。有机相合并干燥旋干，溶质用石油醚/乙酸乙酯混合溶液打浆，后过滤得白色固体(400mg,20％产率)。
2.中间体A42-2的合成
将A42-1(290mg,0.79mmol)溶于10mL二氧六环/水(10:1),向其中加入1滴浓硫酸。回流过夜后，冷至室温。加20mL水稀释,水相用乙酸乙酯萃取(20mL*3)后合并干燥旋干，得白色固体(200mg,74％产率)。
3.化合物A42的合成
将化合物A42-2(200mg,0.59mmol)溶于二氯甲烷(20mL)中，依次向其中加入HATU(340mg,0.89mmol)，A1-2(190mg,0.71mmol)和三乙胺(0.3mL)。常温反应3h后，加水(20mL)稀释。水相用二氯甲烷萃取(20mL*3)。有机相合并干燥旋干，溶质用中压制备纯化得白色固体(45mg,13％产率)。
1H NMR(400MHz,DMSO)δ9.16(s,1H),7.84(d,J＝7.5Hz,2H),7.51(d,J＝7.4Hz,2H),7.41(t,J＝7.4Hz,2H),7.31(dt,J＝9.8,7.9Hz,2H),6.55(d,J＝8.6Hz,1H),6.13(d,J＝8.3Hz,1H),5.82(d,J＝8.8Hz,1H),4.45(dd,J＝15.3,7.7Hz,1H),4.07(d,J＝6.5Hz,1H),2.56(s,1H),2.21(d,J＝11.2Hz,1H),2.00(dd,J＝14.3,6.8Hz,3H),1.85(t,J＝5.5Hz,1H),1.78(s,1H),1.64(d,J＝11.4Hz,2H),1.50-1.35(m,4H),1.26(t,J＝11.7Hz,11H),0.90(dd,J＝17.8,6.5Hz,10H).
ESI-MS(M+Na)+:608.
实施例43
化合物A43
化合物A43是如下方法合成的：
1.中间体A43-1的合成
将9-芴甲酸(10g,47.6mmol)溶于50mL DMF中，向其中依次加入HATU(27g,71.0mmol)，氯化铵(25.5g,476.6mmol)和三乙胺(66mL)。常温反应48h后，加水(200mL)稀释。水层用乙酸乙酯萃取(30mL*3)。有机相合并干燥旋干，溶质过柱子纯化得白色固体(1.6g,16％产率)。
2.中间体A43-2的合成
将A43-1(1.4g,6.69mmol)溶于20mL THF中，加入硼烷二甲硫醚溶液(BH3·Me2S)(10M,1.35mL)后回流3h。冷至室温后，用1M HCl淬灭反应。水相用饱和碳酸氢钠调至碱性后用乙酸乙酯萃取(20mL*3)。有机相合并干燥旋干，溶质过柱子纯化得淡黄色固体(540mg,41％产率)。
3.中间体A43-3的合成
将A43-2(540mg,2.77mmol)溶于10mL二氯甲烷中，冰浴下向其中依次加入三乙胺(1.15mL)和三光气(330mg,1.11mmol)。搅拌30min后，向其中加入L-亮氨酸乙酯(590mg,3.01mmol)。常温反应1h后，加水(10mL)淬灭反应。用二氯甲烷萃取(20mL*3)。有机相合并干燥旋干，溶质用石油醚/乙酸乙酯混合溶液打浆，后过滤得白色固体(850mg,80％产率)。
4.中间体A43-4的合成
将A43-3(370mg,0.97mmol)溶于10mL二氧六环/水(10:1),向其中加入1滴浓硫酸。回流过夜后，冷至室温。加20mL水稀释,水相用乙酸乙酯萃取(20mL*3)后合并干燥旋干，得白色固体(240mg,70％产率)。
5.化合物A43的合成
将化合物A43-4(240mg,0.68mmol)溶于二氯甲烷(20mL)中，依次向其中加入HATU(460mg,1.21mmol)，A27-2(250mg,0.94mmol)和三乙胺(0.4mL)。常温反应3h后，加水(20mL)稀释。水相用二氯甲烷萃取(20mL*3)。有机相合并干燥旋干，溶质用中压制备纯化得白色固体(70mg,11％产率)。
1H NMR(400MHz,DMSO)δ9.11(s,1H),7.87(d,J＝7.5Hz,2H),7.60(t,J＝6.7Hz,2H),7.39(td,J＝7.3,2.6Hz,2H),7.31(ddd,J＝15.0,7.5,3.8Hz,2H),6.30(d,J＝8.5Hz,1H),6.20(t,J＝5.7Hz,1H),4.31(dd,J＝14.9,8.5Hz,1H),4.05(dd,J＝12.1,6.6Hz,2H),3.52-3.36(m,2H),2.23-2.13(m,1H),2.05-1.92(m,2H),1.80(dd,J＝14.0,8.0Hz,2H),1.72-1.32(m,6H),1.19(d,J＝13.5Hz,6H),0.84(ddd,J＝13.9,12.1,7.0Hz,17H).
ESI-MS(M+Na)+:622.1.
实施例44
化合物A44
/>
化合物A44是按如下方法合成的：
1.中间体A44-1的合成
将环戊胺(115mg,1.35mmol)溶于10mL二氯甲烷中，冰浴下向其中依次加入三乙胺(270mg,2.67mmol)和三光气(160mg,0.54mmol)。反应30min后，加入L-色氨酸盐酸盐(325mg,1.35mmol)。常温反应1h后，加1M HCl调至酸性。用二氯甲烷萃取(20mL*3)。有机相合并干燥旋干，得粗产物(260mg，60％)。
2.化合物A44的合成
将A44-1(260mg,0.82mmol)溶于15mL二氯甲烷中，向其中依次加入HATU(470mg,1.23mmol)，A1-2(260mg,0.98mmol)和三乙胺(125mg,1.24mmol)。常温反应2h后，加水(10mL)稀释。有机相用二氯甲烷萃取(10mL*3)后合并干燥旋干，溶质用中压制备纯化得白色固体(70mg，15％产率)。
1H NMR(400MHz,DMSO)δ10.89(s,1H),9.02(s,1H),7.57(d,J＝8.0Hz,1H),7.31(d,J＝8.1Hz,1H),7.14-7.02(m,2H),6.97(t,J＝7.0Hz,1H),6.09(d,J＝7.3Hz,1H),5.85(d,J＝8.3Hz,1H),4.52(dd,J＝14.9,7.0Hz,1H),4.08(d,J＝6.6Hz,1H),3.80(dd,J＝13.2,6.5Hz,1H),3.07-2.89(m,2H),2.49-2.45(m,2H),2.27-2.15(m,1H),2.00(d,J＝7.7Hz,1H),1.85(t,J＝5.6Hz,1H),1.79(s,1H),1.77-1.62(m,3H),1.61-1.42(m,5H),1.37(d,J＝9.9Hz,1H),1.25-1.15(m,8H),0.82(dd,J＝11.9,9.4Hz,10H).
ESI-MS(M+Na)+:585.1.
化合物A45合成方法同A44，只需将第一步原料环戊胺换成环戊醇。
实施例45
化合物A45
1H NMR(400MHz,DMSO)δ10.87(s,1H),9.05(s,1H),7.60(d,J＝7.7Hz,1H),7.32(d,J＝8.1Hz,1H),7.24-7.12(m,2H),7.06(t,J＝7.5Hz,1H),6.98(t,J＝7.4Hz,1H),4.86(s,1H),4.42-4.18(m,1H),4.09(d,J＝7.0Hz,1H),3.09-2.88(m,2H),2.51(s,1H),2.27-2.16(m,1H),2.02-1.94(m,1H),1.85(t,J＝5.6Hz,1H),1.80(s,1H),1.76-1.40(m,10H),1.37(d,J＝9.9Hz,1H),1.26-1.17(m,7H),0.86-0.79(m,9H).
ESI-MS(M+Na)+:586.2.
实施例46
化合物A46
化合物A46是按如下方法合成的
1.中间体A46-1的合成
将L-色氨酸甲酯(500mg,2.29mmol),苄溴(550mg,3.21mmol)和碳酸钾(640mg,4.64mmol)溶于10mL DMF中。常温反应2h后，加100mL水稀释。水相用乙酸乙酯萃取(20mL*3)。有机相合并干燥旋干，用制备板纯化得白色固体(420mg,59％产率)。
2.中间体A46-2的合成
将A46-1(420mg,1.36mmol)和LiOH(120mg,2.72mmol)溶于甲醇/水(3:1，24mL)中。70℃反应2h后，旋去甲醇，水相用2M HCl调至酸性。将所得固体过滤得白色固体(350mg，87％产率)。
3.化合A46的合成
将A46-2(350mg,1.19mmol)溶于15mL二氯甲烷中，向其中依次加入HATU(680mg,1.78mmol)，A1-2(380mg,1.43mmol)和三乙胺(580mg,5.74mmol)。常温反应2h后，加水(10mL)稀释。有机相用二氯甲烷萃取(10mL*3)后合并干燥旋干，溶质用中压制备纯化得白色固体(180mg，27％产率)。
1H NMR(400MHz,DMSO)δ10.89(s,1H),9.03(s,1H),7.52(d,J＝7.8Hz,1H),7.35-7.17(m,7H),7.14(d,J＝2.2Hz,1H),7.05(t,J＝7.0Hz,1H),6.95(t,J＝7.0Hz,1H),4.09(d,J＝6.7Hz,1H),3.69(dd,J＝13.2,4.9Hz,1H),3.61-3.55(m,1H),3.51(d,J＝7.2Hz,1H),3.01(tt,J＝14.2,6.9Hz,2H),2.44(d,J＝7.6Hz,1H),2.21(s,2H),1.86(t,J＝5.5Hz,1H),1.79(s,1H),1.65(d,J＝13.9Hz,1H),1.49(ddd,J＝48.1,21.7,8.6Hz,3H),1.29(s,4H),1.16(d,J＝7.5Hz,2H),0.81(dd,J＝19.4,8.4Hz,10H).
ESI-MS(M+H)+:542.2.
实施例47
化合物A47
化合物A47是按如下方法合成的
1.中间体A47-1的合成
将9-芴乙酸(500mg,2.23mmol)，N-羟基丁二酰亚胺(256mg,2.23mmol)和DCC(460mg,2.23mmol)溶于20mL二氯甲烷中。常温反应过夜后，过滤。滤液旋干，溶质用制备板纯化得白色固体(850mg,100％)。
2.中间体A47-2的合成
将L-天冬氨酸-beta-甲酯盐酸盐(490mg,2.66mmol)和碳酸钠(850mg,7.94mmol)溶于二氧六环/水(3：1，16mL)中，冰浴下向其中加入A47-1(850mg,2.33mmol)。常温反应过夜后，旋干溶剂。水相用2M HCl调至酸性后用乙酸乙酯萃取(20mL*3)。有机相合并干燥旋干得淡黄色固体(690mg，83％产率)。
3.化合物A47的合成
将A47-2(690mg,1.95mmol)溶于25mL二氯甲烷中，向其中依次加入HATU(1120mg,2.93mmol)，A1-2(620mg,2.34mmol)和三乙胺(950mg,9.45mmol)。常温反应2h后，加水(20mL)稀释。有机相用二氯甲烷萃取(20mL*3)后合并干燥旋干，溶质用中压制备纯化得白色固体(140mg，11％产率)。
1H NMR(400MHz,DMSO)δ8.65(d,J＝3.8Hz,1H),8.37(d,J＝8.2Hz,1H),7.86(d,J＝7.5Hz,2H),7.53(dd,J＝19.1,7.6Hz,2H),7.38(t,J＝7.3Hz,2H),7.29(t,J＝6.9Hz,2H),4.91(dd,J＝13.6,8.1Hz,1H),4.35(t,J＝7.4Hz,1H),4.15(d,J＝6.7Hz,1H),3.61(d,J＝4.4Hz,3H),2.77-2.58(m,4H),2.46(d,J＝8.1Hz,1H),2.27-2.18(m,1H),2.00(dd,J＝14.5,6.9Hz,1H),1.88(t,J＝5.6Hz,1H),1.80(s,1H),1.68(dd,J＝22.6,10.3Hz,2H),1.40-1.24(m,8H),0.84(dd,J＝17.5,8.9Hz,10H).
ESI-MS(M+Na)+:623.2.
化合物A48的合成方法同A47，只需将原料L-天冬氨酸-beta-甲酯换成L-天冬酰胺或N4-甲基-L-天冬酰胺。
实施例48
化合物A48
1H NMR(400MHz,DMSO)δ8.84(d,J＝36.1Hz,1H),8.26(d,J＝6.9Hz,1H),7.85(d,J＝6.7Hz,2H),7.78(s,1H),7.61-7.46(m,2H),7.37(s,2H),7.29(s,2H),4.93(s,1H),4.34(s,1H),4.10(d,J＝7.4Hz,1H),2.56(d,J＝15.2Hz,7H),1.86(ddd,J＝65.9,58.1,43.7Hz,10H),1.38(d,J＝55.7Hz,3H),1.03-0.65(m,12H).ESI-MS(M+Na)+:622.2.
实施例49
化合物A49
化合物A49是按如下方法合成的：
将A22-1(210mg,0.59mmol)溶于5mL二氯甲烷中，向其中依次加入HATU(340mg,0.89mmol)，A49-1(229mg,0.80mmol)和三乙胺(180mg,1.78mmol)。常温反应2h后，加水(10mL)稀释。有机相用二氯甲烷萃取(10mL*3)后合并干燥旋干，溶质用中压制备纯化得白色固体(180mg，52％产率)。
1H NMR(400MHz,DMSO)δ7.90(d,J＝7.5Hz,2H),7.73(d,J＝7.5Hz,2H),7.68(d,J＝8.2Hz,1H),7.42(t,J＝7.3Hz,2H),7.37-7.28(m,2H),4.33-4.12(m,5H),3.66(t,J＝8.4Hz,1H),3.38(s,1H),2.90(dd,J＝10.5,6.6Hz,1H),2.33-2.21(m,1H),2.09-1.99(m,2H),1.96-1.80(m,4H),1.73-1.55(m,3H),1.53-1.44(m,1H),1.37(td,J＝8.6,4.3Hz,1H),1.31(s,3H),1.28-1.19(m,5H),0.89(dd,J＝11.1,6.6Hz,5H),0.80(d,J＝13.1Hz,3H).
ESI-MS(M+H)+:584.
实施例50
化合物A50
化合物A50是如下方法合成的
将A50-1(367mg,1mmol)溶于5mL二氯甲烷中，向其中依次加入HATU(494mg,1.3mmol)，A1-2(493mg,1.3mmol)和三乙胺(303mg,3mmol)。常温反应2h后，加水(10mL)稀释。有机相用二氯甲烷萃取(10mL*3)后合并干燥旋干，溶质用中压制备纯化得白色固体(58mg，9％产率)。
1H NMR(400MHz,DMSO)δ9.06(s,1H),7.92(d,J＝7.5Hz,2H),7.64(d,J＝7.2Hz,2H),7.44(t,J＝7.4Hz,2H),7.35(t,J＝7.4Hz,2H),4.77(s,1H),4.46(d,J＝7.1Hz,1H),4.33(dt,J＝17.2,6.3Hz,2H),4.10(d,J＝8.2Hz,1H),2.74(s,3H),2.21(d,J＝8.4Hz,1H),2.03(s,1H),1.83(d,J＝20.3Hz,2H),1.62(ddd,J＝43.2,20.8,6.4Hz,4H),1.39-1.28(m,3H),1.25(d,J＝6.4Hz,7H),0.97-0.75(m,15H).
ESI-MS(M+H)+:615.
实施例51
化合物A51
1H NMR(400MHz,DMSO)δ8.84(s,1H),7.89(d,J＝7.5Hz,2H),7.71(d,J＝7.5Hz,2H),7.65(t,J＝6.1Hz,1H),7.42(t,J＝7.4Hz,2H),7.33(t,J＝7.3Hz,2H),4.34-4.16(m,3H),4.06(d,J＝7.3Hz,1H),3.75(d,J＝6.0Hz,2H),2.56(s,1H),2.23–2.13(m,1H),2.05–1.96(m,1H),1.83(t,J＝5.6Hz,1H),1.80-1.73(m,1H),1.72–1.58(m,2H),1.36–1.27(m,2H),1.22(d,J＝9.9Hz,7H),0.89–0.73(m,9H).
化合物A51的合成方法同化合物A22。
实施例52
化合物A52
1H NMR(400MHz,DMSO)δ10.83(s,1H),9.11(d,J＝10.1Hz,1H),8.61(dd,J＝22.6,8.1Hz,1H),8.33(d,J＝13.6Hz,1H),7.94–7.80(m,3H),7.69(d,J＝7.7Hz,1H),7.36(d,J＝2.1Hz,1H),7.34–7.19(m,3H),7.08-6.98(m,2H),4.95-4.84(m,1H),4.14-4.07(m,1H),3.89(s,3H),3.24-3.18(m,2H),2.61-2.55(m,1H),2.27–2.16(m,1H),2.06-1.97(m,1H),1.89–1.76(m,2H),1.72-1.60(m,2H),1.38(t,J＝10.1Hz,1H),1.32–1.21(m,8H),0.85-0.80(m,9H)。
化合物A52的合成方法同化合物A24。
实施例53
化合物A53
1H NMR(400MHz,DMSO)δ11.14(s,1H),9.07(d,J＝7.2Hz,1H),8.95(s,1H),8.44(s,1H),8.34(d,J＝8.0Hz,1H),8.08–7.98(m,1H),5.20(dd,J＝12.9,5.4Hz,1H),4.63(t,J＝7.2Hz,1H),4.08(d,J＝6.6Hz,1H),2.98–2.84(m,1H),2.70–2.52(m,3H),2.25–2.16(m,1H),2.13–2.05(m,1H),2.04-1.97(m,1H),1.84-1.72(m,2H),1.73–1.57(m,2H),1.38(d,J＝7.3Hz,3H),1.33–1.25(m,3H),1.22(t,J＝4.1Hz,6H),0.89–0.74(m,9H)。
化合物A53的合成方法同化合物A24。
实施例54
化合物A54
1H NMR(400MHz,DMSO)δ11.15(d,J＝2.7Hz,1H),9.29(dd,J＝22.3,7.3Hz,1H),8.76(d,J＝3.3Hz,1H),8.08–7.91(m,3H),5.20(ddd,J＝12.9,5.3,2.4Hz,1H),4.64-4.56(m,1H),4.12(d,J＝8.6Hz,1H),2.98–2.82(m,1H),2.68–2.52(m,3H),2.27–2.18(m,1H),2.13–1.97(m,2H),1.86(t,J＝5.4Hz,1H),1.83-1.75(m,1H),1.71-1.58(m,2H),1.36–1.32(m,4H),1.28–1.19(m,8H),0.87–0.78(m,9H).
化合物A54的合成方法同化合物A24。
实施例55
化合物A55
1H NMR(400MHz,DMSO)δ8.92–8.79(m,1H),8.25–8.12(m,1H),7.24(t,J＝7.9Hz,4H),7.03–6.89(m,6H),4.48–4.38(m,1H),4.38–4.29(m,2H),4.12–4.05(m,1H),2.57–2.51(m,1H),2.24–2.16(m,1H),2.05–1.97(m,1H),1.84(t,J＝5.5Hz,1H),1.80–1.75(m,1H),1.71–1.60(m,2H),1.54–1.38(m,3H),1.36–1.29(m,1H),1.28–1.20(m,8H),0.87–0.72(m,15H).
化合物A55的合成方法同化合物A39。
实施例56
化合物A56
1H NMR(400MHz,DMSO)δ8.94–8.82(m,1H),8.65–8.53(m,2H),8.44–8.42(m,1H),8.21(d,J＝7.7Hz,1H),7.54–7.39(m,2H),7.31–7.22(m,2H),5.22–5.11(m,2H),4.47–4.37(m,1H),4.15–4.06(m,1H),2.60–2.52(m,1H),2.27–2.16(m,1H),2.08–1.98(m,1H),1.89–1.76(m,2H),1.74–1.60(m,3H),1.59–1.42(m,2H),1.34(dt,J＝12.5,6.3Hz,1H),1.30–1.20(m,8H),0.95–0.76(m,15H).
化合物A56的合成方法同化合物39。
实施例57
化合物A57
1H NMR(400MHz,DMSO)δ8.88(dd,J＝18.4,3.1Hz,1H),8.60(dd,J＝27.6,8.4Hz,1H),8.00(t,J＝8.8Hz,2H),7.43(t,J＝7.7Hz,1H),7.34–7.26(m,1H),7.15(t,J＝7.4Hz,1H),7.09(t,J＝1.9Hz,1H),6.80(dd,J＝8.5,1.3Hz,1H),5.13–4.95(m,2H),4.50–4.41(m,1H),4.15–4.09(m,1H),3.85(s,3H),2.59–2.53(m,1H),2.27–2.17(m,1H),2.08–1.98(m,1H),1.89–1.78(m,2H),1.71–1.59(m,3H),1.55–1.43(m,2H),1.38–1.31(m,1H),1.28–1.18(m,8H),0.89(dd,J＝6.3,5.3Hz,3H),0.84–0.80(m,12H).
化合物A57的合成方法同化合物39。
实施例58
化合物A58
1H NMR(400MHz,DMSO)δ9.35(s,1H),8.98(d,J＝2.9Hz,1H),8.71(d,J＝8.2Hz,1H),8.45(d,J＝5.8Hz,1H),8.26(d,J＝7.7Hz,1H),7.58–7.53(m,2H),7.52–7.46(m,1H),7.31(t,J＝7.4Hz,1H),5.13(dd,J＝35.0,16.9Hz,2H),4.47–4.38(m,1H),4.14–4.05(m,1H),2.59–2.53(m,1H),2.26–2.17(m,1H),2.08–1.98(m,1H),1.89–1.77(m,2H),1.71–1.60(m,3H),1.58–1.41(m,2H),1.34(d,J＝10.1Hz,1H),1.31–1.19(m,8H),0.92–0.81(m,15H).
化合物A58的合成方法同化合物39。
实施例59
化合物A59
1H NMR(400MHz,DMSO)δ8.96(s,1H),8.65(d,J＝7.9Hz,1H),8.33(d,J＝1.7Hz,2H),7.59-7.56(m,2H),7.48-7.44(m,2H),5.11(dd,J＝36.1,16.9Hz,2H),4.45–4.34(m,1H),4.09(d,J＝8.5Hz,1H),2.58-2.52(m,1H),2.26-2.16(m,1H),2.07-1.97(m,1H),1.88–1.76(m,2H),1.70-1.57(m,3H),1.57–1.40(m,2H),1.33(d,J＝9.9Hz,1H),1.28-1.15(m,8H),0.93–0.73(m,15H).
化合物A59的合成方法同化合物39。
实施例60
化合物A60
1H NMR(400MHz,DMSO)δ9.00-8.90(m,1H),8.71-8.62(m,1H),8.16(d,J＝7.8Hz,1H),8.00(dd,J＝9.2,2.5Hz,1H),7.56–7.48(m,2H),7.46-7.41(m,1H),7.30–7.23(m,1H),7.20(t,J＝7.4Hz,1H),5.20–4.98(m,2H),4.47-4.40(m,1H),4.16-4.09(m,1H),2.57-2.52(m,1H),2.28–2.17(m,1H),2.08–2.00(m,1H),1.90–1.78(m,2H),1.72–1.60(m,3H),1.57–1.41(m,2H),1.35(d,J＝8.7Hz,1H),1.31–1.16(m,8H),0.95–0.76(m,15H).
化合物A60的合成方法同化合物39。
实施例61
化合物A61
1H NMR(400MHz,DMSO)δ8.99(s,1H),8.68(d,J＝8.2Hz,1H),8.37(d,J＝8.0Hz,1H),8.28(d,J＝7.8Hz,1H),8.16(s,1H),7.60(d,J＝7.8Hz,2H),7.54(t,J＝7.7Hz,1H),7.30(t,J＝7.4Hz,1H),5.26–5.12(m,2H),4.44-4.37(m,1H),4.09(d,J＝6.8Hz,1H),2.58-2.54(m,1H),2.26–2.17(m,1H),2.06-1.95(m,1H),1.87-1.77(m,2H),1.73-1.52(m,4H),1.49-1.40(m,1H),1.31(d,J＝8.1Hz,1H),1.29-1.17(m,8H),0.94–0.78(m,15H).
化合物A61的合成方法同化合物39。
实施例62
化合物A62
1H NMR(400MHz,DMSO)δ8.98(s,1H),8.65(d,J＝8.3Hz,1H),8.16(d,J＝7.7Hz,1H),8.10(d,J＝8.3Hz,1H),7.82(d,J＝1.4Hz,1H),7.52(d,J＝8.2Hz,1H),7.44(t,J＝7.4Hz,1H),7.34(dd,J＝8.3,1.5Hz,1H),7.23(t,J＝7.3Hz,1H),5.10(s,2H),4.43(dd,J＝14.1,9.3Hz,1H),4.10(d,J＝7.0Hz,1H),2.60–2.53(m,1H),2.27–2.16(m,1H),2.07–2.00(m,1H),1.89-1.77(m,2H),1.75-1.52(m,4H),1.50–1.41(m,1H),1.33(d,J＝10.2Hz,1H),1.28–1.22(m,8H),0.92-0.80(m,15H).
化合物A62的合成方法同化合物39。
实施例63
化合物A63
1H NMR(400MHz,DMSO)δ9.00–8.85(m,1H),8.73(dd,J＝19.6,8.3Hz,1H),8.56(d,J＝4.5Hz,1H),8.27(d,J＝7.8Hz,1H),8.13(d,J＝7.3Hz,1H),7.60(ddd,J＝18.2,14.1,7.3Hz,3H),7.34(t,J＝7.3Hz,1H),5.31-5.12(m,2H),4.46-4.38(m,1H),4.16-4.08(m,1H),2.53(d,J＝8.4Hz,1H),2.28–2.13(m,1H),2.09–2.00(m,1H),1.89–1.77(m,2H),1.71–1.58(m,3H),1.56–1.42(m,2H),1.38–1.19(m,10H),0.94–0.75(m,14H).
化合物A63的合成方法同化合物39。
实施例64
化合物A64
1H NMR(400MHz,DMSO)δ8.61(dd,J＝7.7,1.2Hz,2H),8.49(dd,J＝4.8,1.2Hz,2H),8.44(d,J＝8.2Hz,1H),7.85(t,J＝5.5Hz,1H),7.34(dd,J＝7.6,4.9Hz,2H),5.15(q,J＝16.5Hz,2H),4.23(t,J＝7.5Hz,1H),3.06(qd,J＝13.1,6.0Hz,2H),2.23(ddd,J＝17.1,16.7,7.4Hz,1H),2.03–1.74(m,2H),1.72–1.40(m,5H),1.32–1.18(m,9H),0.85(ddd,J＝15.9,11.4,5.2Hz,16H).
化合物A64的合成方法同化合物39。
实施例65
化合物A65
化合物A65是如下方法合成的：
将原料A10(150mg,0.25mmol)和化合物异丁基硼酸(102mg,1mmol)溶于甲醇中，加入稀盐酸(1N,1.5mL)，70℃下反应6h。点板监测，原料反应完全。拉干溶剂，直接用中压制备纯化，得到白色固体(42mg,36％产率)。
1H NMR(400MHz,CD3OD)δ7.85(d,J＝7.6Hz,1H),7.66(t,J＝6.8Hz,1H),7.41(t,J＝7.4Hz,1H),7.31(td,J＝7.4,2.3Hz,1H),4.33-4.14(m,4H),3.95(dd,J＝9.0,6.0Hz,1H),3.00(dd,J＝9.1,5.8Hz,1H),1.57-1.44(m,2H),1.44-1.34(m,2H),1.34-1.16(m,3H),0.85(d,J＝6.5Hz,3H),0.82-0.72(m,9H).
ESI-MS(M+H)+:467.
化合物A66-A83合成方法同A65，只需将A10换成相应的硼酸酯。
实施例66
化合物A66：
1H NMR(400MHz,MeOD)δ7.57(d,J＝7.8Hz,1H),7.37-7.24(m,6H),7.14-7.07(m,2H),7.03(t,J＝7.3Hz,1H),5.05(q,J＝12.4Hz,2H),4.64(t,J＝7.6Hz,1H),3.25(dt,J＝16.2,8.0Hz,2H),2.55(dd,J＝9.5,5.6Hz,1H),1.25-1.16(m,1H),1.12-0.99(m,2H),0.77(t,J＝6.0Hz,6H).
ESI-MS(M+H)+:452.
实施例67
化合物A67：
1H NMR(400MHz,MeOD)δ7.78(d,J＝7.5Hz,2H),7.55(t,J＝9.9Hz,1H),7.48(d,J＝7.5Hz,1H),7.36(t,J＝7.4Hz,2H),7.33-7.23(m,2H),4.72(dd,J＝9.7,5.2Hz,1H),4.38(t,J＝7.4Hz,1H),2.77(dd,J＝14.6,7.0Hz,2H),2.58(dd,J＝14.7,8.0Hz,1H),1.73-1.53(m,4H),1.37(dd,J＝12.9,5.5Hz,2H),0.97(dd,J＝15.0,6.6Hz,12H).
ESI-MS(M+H)+:451.
实施例68
化合物A68：
1H NMR(400MHz,CD3OD)δ7.61(d,J＝7.6Hz,1H),7.32(dd,J＝7.9,3.5Hz,1H),7.14(s,1H),7.11-7.00(m,2H),4.93(d,J＝8.0Hz,1H),3.17(dd,J＝18.1,12.0Hz,1H),2.67-2.57(m,1H),1.95-1.86(m,2H),1.81(d,J＝19.8Hz,3H),1.64(t,J＝14.0Hz,3H),1.56-1.37(m,7H),1.31(d,J＝12.0Hz,5H),1.13(d,J＝5.6Hz,1H),0.89(d,J＝6.8Hz,3H),0.85–0.78(m,3H).
ESI-MS(M+H)+:494.
实施例69
化合物A69
1H NMR(400MHz,MeOD)δ7.60(d,J＝7.7Hz,1H),7.33(d,J＝8.0Hz,1H),7.18-7.00(m,3H),4.87(d,J＝8.4Hz,1H),3.28-3.16(m,2H),2.65-2.54(m,1H),2.22-2.16(m,2H),1.75-1.44(m,6H),1.32-0.95(m,6H),0.90-0.76(m,6H).
ESI-MS(M+Na)+:450.0.
实施例70
化合物A70
1H NMR(400MHz,DMSO)δ10.83(d,J＝26.1Hz,1H),8.67(s,1H),7.92(dd,J＝37.5,8.2Hz,1H),7.53(s,1H),7.32(d,J＝8.1Hz,1H),7.15(dd,J＝21.9,1.9Hz,1H),7.05(t,J＝7.4Hz,1H),6.96(dd,J＝15.9,7.9Hz,1H),4.67(dd,J＝13.5,8.3Hz,1H),4.55–4.45(m,1H),3.25–3.07(m,1H),3.01(dd,J＝14.7,8.7Hz,1H),2.90(t,J＝11.8Hz,1H),2.64(s,1H),2.06–1.90(m,2H),1.59(ddd,J＝25.0,13.3,6.3Hz,1H),1.44–1.16(m,3H),0.84(d,J＝6.2Hz,6H).
ESI-MS(M+H)+:400.
实施例71
化合物A71
1H NMR(400MHz,MeOD)δ7.50(d,J＝7.8Hz,1H),7.37-7.27(m,4H),7.22(dd,J＝7.7,1.6Hz,2H),7.14-7.03(m,3H),4.24(dd,J＝8.4,7.1Hz,1H),4.11(d,J＝13.8Hz,1H),4.01(d,J＝13.8Hz,1H),3.21(dd,J＝14.1,8.5Hz,1H),3.11(dd,J＝14.1,6.9Hz,1H),2.58(dd,J＝9.8,5.4Hz,1H),1.18(dq,J＝12.7,6.4Hz,1H),1.12-0.96(m,2H),0.81-0.72(m,6H).
ESI-MS(M+H)+:472.
实施例72
化合物A72
1H NMR(400MHz,MeOD)δ8.68(dd,J＝4.5,1.6Hz,2H),7.73(dd,J＝4.5,1.6Hz,2H),7.64(d,J＝7.8Hz,1H),7.34(d,J＝8.0Hz,1H),7.17(s,1H),7.08(ddd,J＝14.9,13.9,7.0Hz,2H),5.05(dd,J＝8.5,7.3Hz,1H),3.45-3.33(m,2H),2.61(dd,J＝9.6,5.6Hz,1H),1.35-1.19(m,2H),1.10-1.04(m,1H),0.79(t,J＝6.4Hz,6H).
ESI-MS(M+H)+:423.
实施例73
化合物A73
/>
1H NMR(400MHz,MeOD)δ8.09(dt,J＝12.6,6.5Hz,2H),7.72-7.49(m,3H),7.34(d,J＝8.0Hz,1H),7.21(d,J＝4.3Hz,1H),7.07(dt,J＝25.7,7.2Hz,2H),5.10(dd,J＝15.9,8.6Hz,1H),3.54-3.37(m,2H),2.64(dd,J＝9.2,6.2Hz,1H),1.31(dd,J＝14.1,6.7Hz,2H),1.18-1.09(m,1H),0.83(ddd,J＝20.3,6.4,4.2Hz,6H).
ESI-MS(M+H)+:479.
实施例74
化合物A74
1H NMR(400MHz,MeOD)δ8.95(dd,J＝4.3,1.6Hz,1H),8.45(d,J＝8.4Hz,1H),8.39(d,J＝1.7Hz,1H),8.12(dt,J＝19.3,5.4Hz,2H),7.68(d,J＝7.7Hz,1H),7.63(dd,J＝8.3,4.3Hz,1H),7.36(d,J＝8.0Hz,1H),7.20(s,1H),7.09(dt,J＝23.0,7.0Hz,2H),5.12(t,J＝7.8Hz,1H),3.55-3.39(m,2H),2.63(dd,J＝9.6,5.7Hz,1H),1.27(d,J＝19.9Hz,3H),1.13-1.05(m,2H),0.80(t,J＝6.6Hz,6H).
ESI-MS(M+H)+:473.
实施例75
化合物A75
1H NMR(400MHz,MeOD)δ9.14(d,J＝20.0Hz,1H),8.66(d,J＝34.7Hz,1H),8.12-7.93(m,2H),7.87(d,J＝5.5Hz,1H),7.68(t,J＝7.3Hz,2H),7.35(d,J＝8.1Hz,1H),7.22(d,J＝5.1Hz,1H),7.08(dt,J＝13.7,6.7Hz,2H),5.18(dt,J＝15.3,7.4Hz,1H),3.54-3.35(m,2H),2.73-2.58(m,1H),1.39-1.21(m,2H),1.16-1.06(m,1H),0.92-0.74(m,6H).
ESI-MS(M+H)+:473.
实施例76
化合物A76
1H NMR(400MHz,MeOD)δ8.29(d,J＝28.9Hz,1H),7.98-7.88(m,3H),7.82(ddd,J＝16.7,8.6,1.8Hz,1H),7.69(t,J＝7.1Hz,1H),7.63-7.51(m,2H),7.36(d,J＝7.8Hz,1H),7.21(d,J＝4.6Hz,1H),7.16-7.03(m,2H),5.24-5.07(m,1H),3.57-3.38(m,2H),2.72-2.56(m,1H),1.37-1.26(m,2H),1.14-1.06(m,1H),0.91-0.75(m,6H).
ESI-MS(M+H)+:472.
实施例77
化合物A77
1H NMR(400MHz,MeOD)δ7.60(d,J＝7.7Hz,1H),7.33(d,J＝8.0Hz,1H),7.14-7.00(m,3H),4.74(t,J＝7.4Hz,1H),3.92(p,J＝6.4Hz,1H),3.19(d,J＝7.4Hz,2H),2.57(dd,J＝9.5,5.8Hz,1H),1.87(dt,J＝12.8,6.5Hz,2H),1.73-1.53(m,4H),1.35-1.20(m,3H),1.17-1.01(m,2H),0.79(dd,J＝6.5,4.1Hz,6H).
ESI-MS(M+Na)+:450.9.
实施例78
化合物A78
1H NMR(400MHz,MeOD)δ7.59(d,J＝7.8Hz,1H),7.34(d,J＝8.0Hz,1H),7.17–7.00(m,3H),4.96(d,J＝19.7Hz,1H),4.61(t,J＝7.6Hz,1H),3.28-3.12(m,2H),2.57(dd,J＝9.5,5.4Hz,1H),1.89-1.45(m,8H),1.31-0.99(m,3H),0.79(t,J＝6.3Hz,6H).
ESI-MS(M+Na)+:452.2.
实施例79
化合物A79
1H NMR(400MHz,MeOD)δ7.52(d,J＝7.8Hz,1H),7.34(d,J＝8.1Hz,1H),7.30-7.18(m,5H),7.13-7.06(m,2H),7.04-6.97(m,1H),3.74(dd,J＝14.8,10.2Hz,2H),3.62(d,J＝13.1Hz,1H),3.24-3.15(m,2H),2.56(dd,J＝9.8,5.5Hz,1H),1.24(dd,J＝12.6,6.4Hz,1H),1.18-1.00(m,2H),0.80(dd,J＝6.5,4.8Hz,6H).
ESI-MS(M-H2O)+:390.1.
实施例80
化合物A80
1H NMR(400MHz,MeOD)δ7.78(d,J＝7.5Hz,2H),7.53(dd,J＝17.4,7.4Hz,2H),7.37(t,J＝7.4Hz,2H),7.30(td,J＝7.4,2.7Hz,2H),5.11(t,J＝6.7Hz,1H),4.39(t,J＝7.4Hz,1H),3.70(s,3H),2.88(d,J＝6.7Hz,2H),2.83-2.70(m,2H),2.60(dd,J＝14.8,7.9Hz,1H),1.69(dt,J＝13.6,6.7Hz,1H),1.38(t,J＝7.3Hz,2H),0.93(t,J＝9.8Hz,6H).
ESI-MS(M+Na)+:489.
实施例81
化合物A81
1H NMR(400MHz,MeOD)δ7.78(d,J＝7.4Hz,2H),7.54(dd,J＝17.9,7.5Hz,2H),7.36(t,J＝7.5Hz,2H),7.31(dt,J＝11.7,3.7Hz,2H),5.11(t,J＝6.6Hz,1H),4.59(s,4H),4.39(t,J＝7.4Hz,1H),2.83-2.68(m,4H),2.67-2.57(m,1H),1.68(dd,J＝13.5,7.0Hz,1H),1.39(dd,J＝15.2,7.5Hz,2H),0.93(t,J＝9.4Hz,6H).
ESI-MS(M+Na)+:474.
实施例82
化合物A82
1H NMR(400MHz,MeOD)δ7.80(d,J＝7.5Hz,2H),7.70-7.58(m,2H),7.39(t,J＝7.4Hz,2H),7.32(q,J＝7.4Hz,2H),4.46-4.37(m,2H),4.21(t,J＝6.6Hz,1H),3.72(t,J＝9.6Hz,1H),3.41(dd,J＝17.1,9.9Hz,1H),3.07(dd,J＝11.2,6.4Hz,1H),2.85(d,J＝7.2Hz,1H),2.14(d,J＝9.9Hz,1H),2.03-1.88(m,2H),1.76-1.42(m,4H),0.94(dt,J＝18.1,9.1Hz,5H).
ESI-MS(M+H)+:451.
实施例83
化合物A83
1H NMR(400MHz,MeOD)δ7.80(d,J＝7.5Hz,2H),7.61(t,J＝6.6Hz,2H),7.40(t,J＝7.4Hz,2H),7.31(t,J＝7.4Hz,2H),5.02-4.90(m,1H),4.57(d,J＝6.5Hz,2H),4.48(d,J＝5.8Hz,1H),4.26(t,J＝5.8Hz,1H),2.78(d,J＝29.8Hz,3H),2.65(t,J＝7.5Hz,1H),1.78(s,1H),1.62(ddd,J＝20.6,13.7,7.7Hz,2H),1.40-1.26(m,3H),0.93(dd,J＝17.9,6.5Hz,12H).
ESI-MS(M+H)+:481.
实施例84
化合物A84
1H NMR(400MHz,CD3OD)δ7.80(d,J＝7.5Hz,2H),7.64(t,J＝13.9Hz,2H),7.39(t,J＝7.4Hz,2H),7.31(t,J＝7.4Hz,2H),4.47–4.32(m,2H),4.23(t,J＝6.8Hz,1H),4.01(s,2H),2.70(t,J＝7.6Hz,1H),1.71-1.61(m,1H),1.34(t,J＝7.3Hz,2H),0.91(d,J＝6.6Hz,6H).
化合物A84合成方法同化合物A51。
实施例85
化合物A85
1H NMR(400MHz,CD3OD)δ7.80(d,J＝7.5Hz,2H),7.71–7.60(m,2H),7.39(t,J＝7.4Hz,2H),7.32(t,J＝7.4Hz,2H),4.47–4.31(m,3H),4.22(t,J＝6.6Hz,1H),2.68(t,J＝7.5Hz,1H),1.72-1.62(m,1H),1.39(t,J＝9.8Hz,3H),1.34(t,J＝7.3Hz,2H),0.91(d,J＝6.6Hz,6H).
化合物A85合成方法同化合物A51。
实施例86
化合物A86
1H NMR(400MHz,CD3OD)δ7.80(d,J＝7.5Hz,2H),7.67(t,J＝6.8Hz,2H),7.39(t,J＝7.4Hz,2H),7.32(t,J＝7.4Hz,2H),4.44–4.33(m,3H),4.22(t,J＝6.7Hz,1H),2.69(t,J＝7.6Hz,1H),1.70-1.58(m,1H),1.41(d,J＝7.2Hz,3H),1.32(t,J＝7.3Hz,2H),0.91(d,J＝6.6Hz,6H).
化合物A86合成方法同化合物A51。
实施例87
化合物A87
1H NMR(400MHz,CD3OD)δ8.26–8.14(m,1H),7.87–7.74(m,3H),7.69(dd,J＝7.2,6.3Hz,1H),7.36(d,J＝7.9Hz,1H),7.28(dd,J＝5.2,2.5Hz,1H),7.23–7.16(m,2H),7.16–7.00(m,2H),5.21–5.07(m,1H),3.93(s,3H),3.55–3.34(m,2H),2.67-2.61(m,1H),1.38–1.31(m,1H),1.30–1.02(m,2H),0.89-0.78(m,6H).
化合物A87合成方法同化合物A51。
实施例88
化合物A88
1H NMR(400MHz,CD3OD)δ8.10(d,J＝25.3Hz,1H),7.72–7.63(m,3H),7.55(t,J＝8.3Hz,1H),7.36(d,J＝7.8Hz,1H),7.20(d,J＝3.5Hz,1H),7.15–7.02(m,3H),6.97(dd,J＝4.5,2.2Hz,1H),5.17-5.07(m,1H),3.50-3.36(m,2H),2.68-2.59(m,1H),1.65-1.54(m,1H),1.39-1.31(m,2H),0.91-0.78(m,6H).
化合物A88合成方法同化合物A51。
实施例89
化合物A89
1H NMR(400MHz,CD3OD)δ7.79(d,J＝7.4Hz,2H),7.65(dd,J＝7.1,3.2Hz,2H),7.39(t,J＝7.4Hz,2H),7.33–7.15(m,17H),4.68(dd,J＝7.6,5.4Hz,1H),4.47-4.37(m,2H),4.21(t,J＝6.5Hz,1H),2.94–2.67(m,3H),1.69–1.56(m,1H),1.38-1.27(m,2H),0.93–0.81(m,6H).
化合物A89合成方法同化合物A51。
实施例90
化合物A90
1H NMR(400MHz,CD3OD)δ8.37(d,J＝0.7Hz,1H),8.32(dd,J＝7.8,1.5Hz,1H),8.00(dd,J＝7.8,0.6Hz,1H),5.18(dd,J＝12.5,5.5Hz,1H),4.81–4.76(m,1H),2.94–2.69(m,4H),2.22–2.11(m,1H),1.73–1.60(m,1H),1.56(d,J＝8.6Hz,3H),1.36(t,J＝7.3Hz,2H),0.93(d,J＝6.6Hz,6H).
化合物A90合成方法同化合物A51。
实施例91
化合物A91
1H NMR(400MHz,CD3OD)δ8.17–8.07(m,2H),7.99(t,J＝7.6Hz,1H),5.25(dd,J＝12.6,5.5Hz,1H),4.59(s,1H),3.00–2.86(m,1H),2.85–2.70(m,3H),2.26-2.17(m,1H),1.77–1.62(m,1H),1.56(d,J＝10.9Hz,3H),1.46–1.32(m,2H),0.98–0.89(m,6H).
化合物A91合成方法同化合物A51。
实施例92
化合物A92
1H NMR(400MHz,CD3OD)δ8.86(s,1H),8.36(d,J＝5.3Hz,1H),8.24(d,J＝7.9Hz,1H),8.15(d,J＝5.3Hz,1H),7.67–7.60(m,1H),7.56(d,J＝8.3Hz,1H),7.34(t,J＝7.4Hz,1H),5.31–5.11(m,2H),4.64–4.57(m,1H),2.66(t,J＝7.6Hz,1H),1.82–1.66(m,2H),1.65–1.55(m,2H),1.28(t,J＝7.3Hz,2H),0.98(d,J＝6.3Hz,3H),0.92(d,J＝6.3Hz,3H),0.88(d,J＝6.6Hz,6H).
化合物A92合成方法同化合物A51。
实施例93
化合物A93
1H NMR(400MHz,CD3OD)δ7.26(t,J＝7.9Hz,4H),7.08–7.01(m,4H),6.98(t,J＝7.4Hz,2H),4.72–4.63(m,1H),4.48–4.34(m,2H),2.74–2.62(m,1H),1.72–1.59(m,2H),1.58–1.37(m,2H),1.40–1.29(m,2H),0.92–0.82(m,12H).
化合物A93合成方法同化合物A51。
实施例94
化合物A94
1H NMR(400MHz,CD3OD)δ8.49(dd,J＝7.7,1.1Hz,1H),8.41(dt,J＝4.9,1.6Hz,1H),8.15(d,J＝7.8Hz,1H),7.56–7.45(m,2H),7.34–7.24(m,2H),5.28–5.14(m,2H),4.72–4.61(m,1H),2.67(t,J＝7.6Hz,1H),1.78–1.57(m,4H),1.36–1.27(m,2H),1.00–0.85(m,12H).
化合物A94合成方法同化合物A51。
实施例95
化合物A95
1H NMR(400MHz,CD3OD)δ7.95(dd,J＝12.0,8.1Hz,2H),7.40–7.29(m,2H),7.18(dd,J＝10.7,4.5Hz,1H),6.95(t,J＝2.2Hz,1H),6.84(dd,J＝8.5,1.6Hz,1H),5.09–4.96(m,2H),4.73–4.63(m,1H),3.90(s,3H),2.70–2.61(m,1H),1.75–1.54(m,4H),1.32–1.27(m,2H),0.96–0.86(m,12H).
化合物A95合成方法同化合物A51。
实施例96
化合物A96
1H NMR(400MHz,CD3OD)δ9.29(s,1H),8.54–8.37(m,1H),8.26(d,J＝7.8Hz,1H),7.64–7.53(m,3H),7.44–7.35(m,1H),5.28–5.10(m,2H),4.67–4.62(m,1H),2.68(t,J＝7.6Hz,1H),1.84–1.68(m,2H),1.66–1.54(m,2H),1.32–1.27(m,2H),1.01–0.86(m,12H).
化合物A96合成方法同化合物A51。
实施例97
化合物A97
1H NMR(400MHz,CD3OD)δ8.09(s,2H),7.43(s,4H),5.08(q,J＝16.9Hz,2H),4.63-4.59(m,1H),2.67(t,J＝7.5Hz,1H),1.80–1.54(m,4H),1.31-1.27(m,2H),1.02–0.85(m,12H).
化合物A97合成方法同化合物A51。
实施例98
化合物A98
1H NMR(400MHz,CD3OD)δ8.07(d,J＝7.8Hz,1H),7.80(d,J＝8.9Hz,1H),7.50–7.38(m,3H),7.24-7.17(m,2H),5.14-5.02(m,2H),4.67-4.61(m,1H),2.67(t,J＝7.3Hz,1H),1.77–1.52(m,4H),1.38-1.24(m,2H),1.01–0.87(m,12H).
化合物A98合成方法同化合物A51。
实施例99
化合物A99
1H NMR(400MHz,CD3OD)δ8.06(dd,J＝12.1,8.1Hz,2H),7.50–7.40(m,3H),7.24(dd,J＝10.6,5.1Hz,1H),7.20(d,J＝8.3Hz,1H),5.13-5.02(m,2H),4.67-4.63(m,1H),2.71-2.63(m,1H),1.78–1.55(m,4H),1.33-1.26(m,2H),1.02–0.88(m,12H).
化合物A99合成方法同化合物A51。
实施例100
化合物A100
1H NMR(400MHz,CD3OD)δ8.04(d,J＝8.3Hz,2H),7.51(d,J＝1.6Hz,2H),7.23(dd,J＝8.3,1.7Hz,2H),5.07(s,2H),4.68-4.64(m,1H),2.68(t,J＝7.6Hz,1H),1.77–1.56(m,4H),1.29–1.25(m,2H),1.01–0.89(m,12H).
化合物A100合成方法同化合物A51。
实施例101
化合物A101
1H NMR(400MHz,CD3OD)δ8.26(d,J＝8.0Hz,1H),8.20(d,J＝7.9Hz,1H),7.90(s,1H),7.55-7.52(m,3H),7.32(t,J＝7.3Hz,1H),5.24–5.10(m,2H),4.63(dd,J＝9.5,5.5Hz,1H),2.67(t,J＝7.6Hz,1H),1.81–1.67(m,2H),1.66-1.56(m,2H),1.31-1.27(m,2H),1.03–0.87(m,12H).
化合物A101合成方法同化合物A51。
实施例102
化合物A102
1H NMR(400MHz,CD3OD)δ8.08(d,J＝7.8Hz,1H),7.99(d,J＝8.3Hz,1H),7.64(d,J＝1.4Hz,1H),7.50–7.41(m,2H),7.34(dd,J＝8.3,1.5Hz,1H),7.29–7.21(m,1H),5.13–5.01(m,2H),4.67–4.60(m,1H),2.68(t,J＝7.6Hz,1H),1.80–1.66(m,2H),1.67–1.56(m,2H),1.32-1.28(m,2H),1.02–0.85(m,12H).
化合物A102合成方法同化合物A51。
实施例103
化合物A103
1H NMR(400MHz,CD3OD)δ8.07-8.04(m,2H),7.45–7.38(m,2H),7.27–7.16(m,2H),7.00-6.94(m,1H),5.06(q,J＝17.2Hz,2H),4.67-4.63(m,1H),2.67(t,J＝7.6Hz,1H),1.82–1.55(m,4H),1.34–1.28(m,2H),1.01–0.84(m,12H).
化合物A103合成方法同化合物A51。
实施例104
化合物A104
1H NMR(400MHz,CD3OD)δ8.45(d,J＝4.7Hz,1H),8.32(d,J＝7.8Hz,1H),7.97–7.89(m,1H),7.62–7.44(m,3H),7.34(t,J＝7.4Hz,1H),5.23–5.06(m,2H),4.72-4.60(m,1H),2.67(t,J＝7.6Hz,1H),1.81–1.55(m,4H),1.29(t,J＝7.3Hz,2H),1.00–0.83(m,12H).
化合物A104合成方法同化合物A51。
实施例105
化合物A105
1H NMR(400MHz,CD3OD)δ7.96(t,J＝8.1Hz,2H),7.49(d,J＝7.3Hz,2H),7.42–7.29(m,5H),7.18(t,J＝7.2Hz,1H),7.06(d,J＝2.1Hz,1H),6.92(dd,J＝8.5,2.1Hz,1H),5.21–5.13(m,2H),5.09–4.97(m,2H),4.66-4.62(m,1H),2.66(t,J＝7.6Hz,1H),1.76–1.51(m,4H),1.35-1.26(m,2H),0.95-0.85(m,12H).
化合物A105合成方法同化合物A51。
实施例106
化合物A106
1H NMR(400MHz,CD3OD)δ7.94(d,J＝7.7Hz,1H),7.86(d,J＝8.4Hz,1H),7.36-7.29(m,2H),7.20–7.11(m,1H),6.80–6.70(m,2H),5.06–4.91(m,2H),4.69-4.64(m,1H),2.68(t,J＝7.6Hz,1H),1.77–1.50(m,4H),1.31–1.24(m,2H),1.00–0.85(m,12H).
化合物A106合成方法同化合物A51。
实施例107
化合物A107
/>
1H NMR(400MHz,CD3OD)δ8.56(dd,J＝7.7,1.4Hz,2H),8.49(dd,J＝5.0,1.4Hz,2H),7.36(dd,J＝7.7,5.0Hz,2H),5.39–5.25(m,2H),4.63(dd,J＝9.4,5.4Hz,1H),2.67(t,J＝7.2Hz,1H),1.85–1.61(m,4H),1.15(t,J＝7.2Hz,3H),1.00-0.86(m,12H).
化合物A107合成方法同化合物A51。
效果例1：本发明化合物的抗癌活性测试
实验方法：
1.细胞培养方法。
细胞培养基：洛维斯培养基RPMI-1640(+左旋谷氨酰胺)中加入10％胎牛血清，每毫升100单位青霉素、100μg链霉素。
细胞培养条件：5％CO2，95％湿度，37℃恒温培养。
2.细胞接种、加药培养。
将对数生长期的HL-60、人慢性髓系白血病细胞(K562)、人食管鳞癌细胞(KYSE510)、人大细胞肺癌细胞(H460)细胞接种至96-孔细胞培养板中，每孔2×104细胞。加入不同浓度的活性化合物(溶于二甲亚砜(DMSO)储液)，DMSO终浓度为0.2％，对照组为DMSO。每组重复三次。
3.MTT实验。
培养72小时后，每孔加入20μL的噻唑蓝(MTT)(5mg/ml，现配现用，溶于细胞培养用1×PBS)，37℃孵育3小时。
离心96孔细胞培养板，1000rpm，10分钟。弃去上清，每孔加入200μL的DMSO，摇匀5分钟。
用酶标仪检测每孔在570nm波长处的吸收值，计算化合物的IC50。
表1：本发明化合物对HL60细胞抑制作用的IC50值
/>
/>
注：A代表化合物IC50在100nM以下，B代表化合物IC50在100～500nM，C代表化合物IC50在500nM～2μM，D代表化合物IC50在2～10μM之间。
表1,2实验结果显示了本发明化合物对HL60、K562、KYSE510、H460细胞均具有优异的抑制效果，可用于癌症的预防和治疗。
表2：本发明化合物对其他c-Myc高表达细胞抑制作用的IC50值
| 化合物序号 | K562/IC50 | KYSE510/IC50 | H460/IC50 |
| A10 | A | A | A |
| A67 | A | A | A |
| A69 | A | A | A |
注：A代表化合物IC50在100nM以下。
效果例2：本发明化合物对C-myc蛋白的结合效果测试
1.实验准备
将10×PBS-P稀疏成1.05×PBS-P缓冲液备用。将c-Myc370-412-biotin多肽溶解于色谱纯DMSO配制成1mM储液。活性分子溶解于色谱纯DMSO配制成10mM储液。将部分1.05×PBS-P缓冲液加入色谱纯DMSO配制成1.00×PBS-P缓冲液(5％DMSO，现配现用)。
分别测试每个小分子在1.00×PBS-P缓冲液(5％DMSO)体系中可达到的最高溶解度。将该溶解度作为小分子活性测试的最高浓度。
2.蛋白固定
将c-Myc370-412-biotin多肽储液加入1.05×PBS-P缓冲液配制成50μM溶液，再用1.00×PBS-P缓冲液(5％DMSO)稀释至1μg/ml用于固定蛋白。
使用1.00×PBS-P缓冲液(5％DMSO)冲洗芯片样品道和参比道后，选用自动模式固定蛋白在样品道。目标固定蛋白量为500RU。固定成功。缓冲液继续冲洗至平衡。
3.小分子活性测试。
使用缓冲液配置不同浓度的小分子化合物用于样品测试，体系为1.00×PBS-P缓冲液(5％DMSO)。检测小分子流经样品道和参比道响应的差值。
实验条件为流速30μL/min，结合时间为120秒，解离时间为240秒。在每一次结合解离测试后使用50％DMSO冲洗管路，10mM glycine-HCl缓冲液(pH 2.1)冲洗芯片表面以洗去残留的化合物分子。
表2：本发明化合物c-Myc蛋白结合常数测定
| 化合物编号 | SPR Kd | 化合物编号 | SPR Kd |
| A2 | B | A5 | B |
| A3 | B | A6 | A |
| A4 | A | A7 | A |
注：A代表化合物Kd在100nM以下，B代表化合物Kd在100～500nM
本发明内容仅仅举例说明了要求保护的一些具体实施方案，其中一个或更多个技术方案中所记载的技术特征可以与任意的一个或多个技术方案相组合，这些经组合而得到的技术方案也在本申请保护范围内，就像这些经组合而得到的技术方案已经在本发明公开内容中具体记载一样。
Claims (5)
1.化合物或其药学上可用的盐、或立体异构体，所述化合物具有如下结构:
2.一种药物组合物，其包含药学上可接受的载体和权利要求1所述的化合物或其药学上可用的盐或立体异构体。
3.权利要求1所述的化合物或其药学上可用的盐或立体异构体在制备c-Myc蛋白抑制剂中的用途。
4.权利要求1所述的化合物或其药学上可用的盐或立体异构体在制备治疗c-Myc蛋白失调相关疾病药物中的用途，其中所述c-Myc蛋白失调相关疾病选自肺癌、食道癌和白血病。
5.根据权利要求4所述的用途，其中所述白血病为粒细胞性白血病。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910610585 | 2019-07-08 | ||
| CN2019106105851 | 2019-07-08 | ||
| PCT/CN2020/100103 WO2021004391A1 (zh) | 2019-07-08 | 2020-07-03 | 一种c-Myc蛋白抑制剂及其制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114072413A CN114072413A (zh) | 2022-02-18 |
| CN114072413B true CN114072413B (zh) | 2024-04-16 |
Family
ID=74115025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080049295.5A Active CN114072413B (zh) | 2019-07-08 | 2020-07-03 | 一种c-Myc蛋白抑制剂及其制备方法和用途 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20220324884A1 (zh) |
| CN (1) | CN114072413B (zh) |
| WO (1) | WO2021004391A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115504963A (zh) | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
| WO2024027795A1 (zh) * | 2022-08-04 | 2024-02-08 | 苏州开拓药业股份有限公司 | 包含Myc蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090099132A1 (en) * | 2007-10-16 | 2009-04-16 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
| US20140296307A1 (en) * | 2013-03-27 | 2014-10-02 | University Of Maryland, Baltimore | Potent analogues of the c-myc inhibitor 10074-g5 with improved cell permeability |
| CN107522700A (zh) * | 2017-08-03 | 2017-12-29 | 中山大学 | 一种喹唑啉酮与α，β‑不饱和酮轭合衍生物及其制备方法和应用 |
-
2020
- 2020-07-03 CN CN202080049295.5A patent/CN114072413B/zh active Active
- 2020-07-03 US US17/597,311 patent/US20220324884A1/en active Pending
- 2020-07-03 WO PCT/CN2020/100103 patent/WO2021004391A1/zh active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090099132A1 (en) * | 2007-10-16 | 2009-04-16 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
| US20140296307A1 (en) * | 2013-03-27 | 2014-10-02 | University Of Maryland, Baltimore | Potent analogues of the c-myc inhibitor 10074-g5 with improved cell permeability |
| CN107522700A (zh) * | 2017-08-03 | 2017-12-29 | 中山大学 | 一种喹唑啉酮与α，β‑不饱和酮轭合衍生物及其制备方法和应用 |
Non-Patent Citations (4)
| Title |
|---|
| Joanne Tan et al..De Novo Design of Boron-Based Peptidomimetics as Potent Inhibitors of Human ClpP in the Presence of Human ClpX.《J. Med. Chem.》.2019,第62卷6377-6390. * |
| Meng Lei et al..3D-QSAR-aided design, synthesis, in vitro and in vivo evaluation of dipeptidyl boronic acid proteasome inhibitors and mechanism studies.《Bioorganic & Medicinal Chemistry》.2016,第24卷2576-2588. * |
| Stanley C. Xie et al..Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome.《J. Med. Chem.》.2018,第61卷10053-10066. * |
| Yongqiang Zhu et al..Design, Synthesis, Biological Evaluation, and Structure-Activity Relationship (SAR) Discussion of Dipeptidyl Boronate Proteasome Inhibitors, Part I:Comprehensive Understanding of the SAR of r-Amino Acid Boronates.《J. Med. Chem.》.2009,第52卷4192-4199. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114072413A (zh) | 2022-02-18 |
| WO2021004391A1 (zh) | 2021-01-14 |
| US20220324884A1 (en) | 2022-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3070089B1 (en) | Aminomethyl tryptanthrin derivative, preparation method and application thereof | |
| EP2949647B1 (en) | Deuterated phenyl amino pyrimidine compound and pharmaceutical composition containing same | |
| CN108314677B (zh) | 一种ezh2抑制剂及其用途 | |
| JP2016535788A5 (zh) | ||
| JP2018528199A (ja) | Ｐａｒｐ阻害剤の製造方法、結晶型、及びその使用 | |
| CN114072413B (zh) | 一种c-Myc蛋白抑制剂及其制备方法和用途 | |
| AU2016284383B2 (en) | Crystal of (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1- yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4- hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2Hpyrazino[ 2,1-c][1,2,4]triazine-1-(6H)-carboxamide | |
| CN112300153B (zh) | 一种杂环化合物、药物组合物和用途 | |
| CN110627801B (zh) | 一类hdac抑制剂及其用途 | |
| CN108969522B (zh) | N-苄基色胺酮类衍生物作为色氨酸双加氧酶(tdo)抑制剂的用途 | |
| CN113234116B (zh) | 一种雷公藤红素衍生物及其制备方法和医用用途 | |
| CN110028546B (zh) | 具有调控凝血因子viii水平发挥抗肿瘤作用的环戊烷并多氢菲骨架化合物及其用途 | |
| CN112480140B (zh) | C5-位取代汉防己甲素衍生物及其制备方法和应用 | |
| EP3730484A1 (en) | Indoleamine-2,3-dioxygenase inhibitor, preparation method therefor, and application thereof | |
| WO2022089556A1 (zh) | 一种c-Myc蛋白抑制剂及其制备方法和用途 | |
| CN108456214B (zh) | 含噁唑或咪唑结构的喹唑啉类化合物及其应用 | |
| CN115433207A (zh) | 作为egfr抑制剂的大环杂环类化合物及其应用 | |
| CN109748914B (zh) | 吡啶并嘧啶类化合物及其应用 | |
| CN108640965B (zh) | 2-取代-18β-甘草次酸衍生物及其应用 | |
| EP3369740A1 (en) | New cytidine derivative dimers and applications thereof | |
| CN110343098B (zh) | 一类噁二唑类化合物及其制备方法、药物组合物和用途 | |
| CN102485735B (zh) | 6-果糖氨-4-芳胺基喹唑啉衍生物及其用途 | |
| CN110143948B (zh) | Cdk4/6抑制剂、其药物组合物、制备方法及应用 | |
| CN115232130B (zh) | 一种apn和akt双靶点抑制剂及其制备方法和应用 | |
| CN115368306B (zh) | 含四氢异喹啉类结构的hdac抑制剂、组合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |